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Abstract
BAG· I (BCL.2 associated anti-death gene) is a multi-isofonn, BCL-2 binding
protein having anti-aplptotic capabilities. In addition to binding BCL-2, BAG· I has been
found to bind and regulate the function of various steroid honnone receptors. It is postulated
that BAG·I's ability to inhibit apoptosis and proliferation induced by honnone receptors
could lead to nunor growth if BAG-I were to becomeoverexpressed. In fact, BAG-I has
been found to be overexpr-e:ssed in ceMCal and breast twnors indicating that BAG·} may be
a proto-oncogene. To further investigate BAG·} 's role in steroid honnone regulation, I
decided to investigate whether or not BAG-I could bind and regulate another member ofthe
steroid hormone receptor super family - the vitamin D 3 receptor.
Far Western blot analysis and glutathione S·transferasc .BAGpSO pull-down assays
revealed that the fuJI length SO KDa isofonn of BAG-I could interact with the vitamin D
receptor(VDR). The shorter isofonns however, could nolo Gel shift assays using cell extracts
from BAGpSO stably ttansfected US7 glioblastoma cells (US7BAG·I) showed that BAG-I
could inhibit the VDR from binding to its consenus response elemenl, as well as a vitamin
D response element (YORE) from the p21 ....n promoter. Furthermore, overexpression of
BAGpSO not only resulted in an increased Tate ofproliferation but rendered the cells resistant
to vitamin D-induced growth inhibition. A CAT construct containing a osteocalcin YORE
was employed to demonstrate that BAGpSO could also inhibit vitamin D·mediatcd gene
expression. This was further illustrated by the fact that the presence ofBAGpSO in US7 cells
blocked the induction ofVOR prolein levels in response to vitamin 03.
Because BAGpSO could block vitamin D3-mediated transcription of the osteocaIcin
VDRE it was decided to investigate whether BAGpSO could block vitamin D3-mediated
upregulation ofp21 wdl transcription. Using p21 ....n luciferue col1Stlllcts. it was found that
BAGpSO could inhibit vitamin 03 activation ofp21 ....n transcription. Interestingly. the p46
isofonn of BAG-I decreased the level of p21..,,(l transcription through an unknown
mechanism.
These results demonstrate for the first time that BAGpSO can bind and regulate the
function of the VDR. It was also found that BAG-I may act as a regulator of proliferation.
BAGpSO and p46 could also regulate the transcription of p21....n through two separate
mechanisms, suggesting that different isoforms of BAG-I may work together to achieve the
common goal of promoting cell proliferation.
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CHAPTER I
INTRODUCTION
1.1 StruetllreofBAG-1
BAG-I (BCL-2 associated anti-death gene I) is a multi-i$Ofonn protein baving
antiapoptotie and pro-proliferative activities. In total, there are four known isofonns ofBAG-
I, having masses of 50,46,33 and 29 lcilodaltons (kDa). forthwith to be described as
BAGp50, BAGp46. BAGp33 and BAGp29 respectively. The full length BAGpSO protein
contains a total of345 amino acids. Each isofonn arises from alternate translational stan sites
(Fig. Lla), with the p50 isofonn of BAG-I being the product ofa rare CTG start site (Yang
et aL. 1998b). Other genes containing alternate sites oftranslation include the oncogenes c-
myc (spons et aI., 1997) and cot (Aolci et aI., 1993).
BAG-I has several structural domains of interest (Fig. I.Ib). The carboxyl (C)
tenninal of the protein. encompassing approximately the last 112 amino acids (Fig. 1.lb
region E), is predicted to assume an a-helical conformation that is highly amphipathic in
nature (Takayamaet ai., 1995). This region has been shown to be important for interactions
with other proteins(Takayamaet aI., 1995 and 1997). Amino acids 169- 200 in the central
region of the protein (Fig. 1.lh region C) have 50% identity (66% similarity) with several
ubiquitin proteins (Takayama et ai., 1995). Although the importance of this region remains
unknown, it is possible that this region may confer upon BAG-J some of the properties of
uhiquitin proteins, such as targeting proteins for degradation.
BAG-I also contains two nuclear localization signals. The first is a simian virus 40-
like nuclear localization signal (SV40NLS) (Fig. 1.1 b region A) that is only found in the p50
isoforrn ( Packham et aJ., 1997) and the second is a bipartite signal (Fig. 1.1b region D)
located in the central portion ofthe protein from amino acids;Z.20 to 235 (Zeiner and Gehring
1995). The SV40NLS seems to acI as a more dominant signal than its bipartite counterpart,
since BAGp50 is found predominately in the cell nucleus while p46 and pH are found in
both the nucleus and cytoplasm and p29 in the cytoplasm. alone. What other factors
contribute to the compartmentalization ofBAG-l remains to be determined, but may include
interaction with other proteins and phosphorylation.
Finally, BAG-I contains ten repeats ofthe following amino acid sequence; TRSEE.
Each repeat being separated by foW" to five highly variable amino acids. Variation in the
consensus occurs primarily within the serine (S) residue. these repeats are found within
amino acids 79·134 (Fig. lb, region B). This domain is believed to have an «-helical
secondary slnJctw'e (packham eJ af., 1997). Significantly, this region is likely an amphipathic
helix with the negatively charged glutamic acid (E) residues localizing on one side of the
helix's spiral and hydrophobic residues on the opposite side. Proteins with this motifare
commonly potenl activators oftranseription (Latchman 1990) and include the retinoic acid
receptor (Durand el aI., 1994). The role of the acidic «-heliJt in activating transcription is
to bind and modulate the activity of the TATA box binding proteins TFIID or TFIlB
(Transcription Factor II B or D) which are a part of the basal transcriptional machinery.
Some proteins having this amphipathic domain do not actually bind DNA. They bind another
protein having DNA binding abilities and fonn a link from this DNA bound transcription
factor to TFDD (Latchman 1990). An example of this is the Ilerpes simplex virus VPI6 (
Stem el aJ., 1989) which binds Oct-I to enable itself 10 consequently bind TFUD.
Fig. 1.la Positioning o( alternate In.slalio.al start sites a.d size o( each iso(orm o(
BAG-I.
Amino acid position ofeach alternate stan site is indicated as is the length of each
isoform. Full length BAGp50 is 345 amino acids and the p46, p33 and p29 isofonns are
274,230 and 207 amino acids in length respectively.
Fig. I.Ib Structural domaias 0(8"G-I
A SV40-like nuclear localization signal
B N-tennmal a-helical domain
C Ubiquitin.like domain
o Bipartite nuclear localization signal
E C·tenninaill-helical domain
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Although it is not known whether or not BAG-I can bind DNA 01'" TFfiD. il has been
reported to have b'anScription regutating properties as will be discussed below.
1.2 F••ctioII or BAG-l
As is clearly seen from the numerous structural domains and multiple isoforms of
BAG·t. this protein has the polcntialto be involved in a number ofcellular functions. In the
lhn:e years since BAG-I has been discovered. this potential has come to fruition with BAG-I
being reportedly involved in functions as diverse as inhibiting apopcosis to regulating protein
folding. In this section. all these functions will be discussed. along with the implications of
each function in regard to cancer.
1.:U BAG-l i11ll11blb apoptosis
Apoptosis is defined as a prognmmed cell death. This process is regulaaed through
a number of mechanisms and OCCUJS in response to a nwnbeT of inttxellular and
extracellular stimuli. During embryo devdopment, cells die to shape and sculpt new tissues
and dispose ofexcess neuronal tissue. In adult animals cells die by apoplosis during tissue
turnover, in response 10 cellular damage and while blood cells die at the end ofan immune
response (Ashkenazi and Dixit 1998). In ol"der for a cell to survive. it must continually
receive extracellular survival signals, thus apoplosis is considered 10 be a cell's default
system and a cell must overcome this default mechanism in order to survive. BAG-! has
been found to inhibit apoptosis induced by a number ofdifferent stimuli (Takayama el al.,
1995; Clevenger et at., 1997). BAG·I has been found ubiquitously in all tissue types studied
thus far. This indicates that a physiological function of BAG· I may be 10 block a cell's
default apoptotic program.
Further evidence for this lies in the fact that BAG·1 can inhJ.bit apoptosis induced by
the retinoic acid and glucocorticoid steroid hormones. As will be discussed latter, steroid
honnone induced apoptosis is important for a number ofphysiological functions (Kiess and
Gallaher 1998). BAG-I has been found to bind the receptors for these honnones and prevent
their normal function (Kullman el 01., 1998; Liu et 01., 1998). Therefore, one mechanism
through which BAG· I could inhibit apoptosis is through regulation ofhormone pathways.
Apoptosis is known to play an important role in twnorigenesis and metastasis.
Nonnally, a cell would die in the event of ONA damage or withdrawal ofgrowth factors.
However, ifa cell is unable to die, DNA damage can accumulate leading to uncontrolled cell
growth. Or, in the event ofa cell being able to survive under non-physiological conditions,
a cancer cell can migrate to a new body tissue and proliferale under conditions where it
nonnally couldn'l survive. Therefore, overexpression ofan antiapoplotic prolein such as
BAG· I can lead to neoplastic growth and possibly metastasis (Iaanda 1999).
1.2.2 IDtuactioa of BAG-l witb oilier proteiD.
Most of the discoveries of potential BAG-l functions have involved its interaction
with olherproteins. This section ofthe thesis will describe in tum the functional significance
of each of the BAG-l binding proleins.
1.2.2.1 BCL-2
BAG-I was originally cloned due to its ability to bind the BCL·2 protein. lbcir
ability to bind was discovered by screcni.ng a mouse embryo library with the BCL-2 protein.
BCL.2 is a potent inhibitor ofapoptosis and bas been dircctJy implicated in the dc:veklpmenl
of malignant lymphoma (faljimolO eraL. 1985) aDd indirectly in othel" caIlCefS such as
thoseoftbe bead and neck (GaIJo er aL. 1995). Theoverexpression ofBCL-2 in cancerccll
lines has been found 10 make lhem resistanl to many apoptosis·inducmg stimuli. including
cisplatin (Miyake et 01., 1998), oxidative str:ss (Fabisiak: et 01., 1997), glucocorticoids and
vincristine (Miyashila and Reed 1993). By CO--lranSfccting BAG-I and BCL·2 into a number
of cell lines, researchers have found thai BAG-I can enhance !he abilily ofBCL-2 10 block
the action of a number of apoplosis·inducing agcnls such as Slallrosporine. anli-FAS
antibody, (Takayama et 01., 1995) and withdrawal of growth faclors (Clevenger ct 01., 1997)
in various types orulls. As well, BAG-I was foWK1lo independently confer resistance 10
Slaurosporinc in NIH3TI mouse fibroblasts (Takayama ct 01., 1995).
II is wellicnown that the activation of proteases is an integral part of the apoplotic
process. A Iargc family of these prnlcasc:san: refem:d to as caspases. The action of caspascs
is known to be blocked by BCL.2. U has been foWK1 in neuronal cells thai overexprcssion
ofBAQ·1 can inhibit caspase activity and can collabot2le with BCL.2 when coexprcsscd 10
inhibil these proteases 10 an even grealer extent than either protein on ils own (Schultz et 01.,
1997).
BCL·2 is primarily localized in the membranes of the mitochondria and nucleus
(Kroemer 1997), while BAG-I is dispersed throughout the entire cell (Yang et aI., 1998b).
Transfection experiments of BAG-l and BCL-2 have shown that BCL-2 can wget BAG-I
10 me mitochondrial and nuclear membranes (Takayama ~ 0.1., 1998), indicating thallhe
interaction oflbe two proteins bas in vil'O significance.
BCL-2 is thoughl 10 prevent cell death through several processes.. These include
preventing the release of the c:aspase activator cytocbnxne c and ca1ciwn from the
nUtochondria(Gtcc:n and Reed 1998), as weU as dccn::asingthe genemioo ofn::active oxygen
species (Kane et o./., 1993), which an:: known to be involved in the apoptotic mechanism.
BCL-2 seems to be involved in the fonnation of membrane ion channels., which may be
involved in regulating me movemenl ofproleins across these membranes (Schendel et 0.1.,
1997). The pore fonning ability BCL-2 may allow il to accomplish such diverse
anliapoplotic actions. The mechanism by which BAG-l enhances the anti-apoplotic effect
of BCL·2 remains WlClear. II can be speculated however, based on the fact thai BAG· I is
involved in protein folding (to be discussed latter), that BAG-I may be involved in
regulating the conformation of~2,which could affect ion channel formation. II is also
possible that the some isofonns ofBAG-) may induce differenl conformations ofBCl-2.
thereby altering its function.
A prolein sucb as BAG-l that is involved in cell survival on its own and in
conjunction with the BCL-2 protein, certainly bas potential to be involved in cancer
formation.. Ifa suppressor ofapoptosis should become overexpressed as the result of some
mutation or chromosomal translocation, the cell may be unable 10 die in the evenl of ONA
damage. thus leading 10 DNA mutations and ultimately in uncontrolled cell growth and
tumor formation. Therefore. the overexpression of BAG-I may be oncogenic. It has yet 10
be shown that BAG-I is directly involved in tumor formation. but it bas recently been
demonstrated that BAG-I can increase pulmonary metastasis in mice(fakaoka er al., 1997)
through a yet uodiscovtnd mechanism. Because BCL-2 has been shown to be involved in
tumorigenesis (8onnotte et al., 1998 and Tsujim010 er aL, 1985), it is reasonable that the
overexpression ofBAO·1 in cells could enhanCe the tumorigenic potential ofBCL-2.
1.2.2.2 RAF·I
RAF-I isa serine/thrconine protein kinase involved in the RAS signal transduc1ion
pathway (Propst et al., 1993). This pathway is important in cellular growth and proliferation.
Constitutive activa1ion or overexpression ofRAF·1 can result in uncontrolled cell growth
and this situation has been found to occur in !lIDg and renal cancers (Propst et al., 1993).
BAG-J was fotu1d to imfnunoprecipi1al.e with the catalytic domain ofRAF-I, similar 10 the
binding ofRAF-l with BCl·2 which results in RAF·l being targeted to the mitochondria
(Wang et aI., 199'6). Unlike BCL--2. BAG-I bas the ability to activa1e the kinase activity of
RAF-I in vitro and in vivo. 1be exac1 mechanism by which BAO_I activates RAF-I is
unknown. It m~)' dislodge negative regulatory proteins from their inter.1Ction with RAF·I,
alter its confo~ion.or target it to other proteins. BAG-I does not Ju.ve the ability 10
activate other proteins via phosphorylatioo (Wang er al., 1996). so this method ofactivation
can probably be ruled out.
The interaction of BAG· I and RAF·t would again lead us to believe that BAG·J has
oncogenic potential. [fcellular BAG·l protein levels were to become overexpresscd. this
might result in II RAF·I activity much higher than the cellular nonn which could lead to
10
uncontrolled cell growth.
1.1.1.3 Hepatocyte Growtll Flidor ud PbICdet Daivtd Growdl FIldGr receplDn
Hepatocyte growth factor receptor (HGFR) is a transmembrane tyrosine kinase
receptor. When stimulated by its ligand (hepa1OCytc growth factor). it initiates a signal
transduction pathway that results in the proliferation of endothelial and epithelial cells
(Nakamura et 01., 1986) as well as promoting the growth of new blood vessels (Camussi et
01., 1997). Santelli et 01., (1996) isolated BAG·I by screening a mouse embryo eDNA
library with the C)1Oplasmic domain ofthc HGFR(8ardelli eJoL. 1996). Using Glutathione-
S-Transferue (OSl) fusion proteins. the BAG-I C-lemUnus was identified as the HGFR
binding domain. Wbc:n the last 83 amiooacids of BAG-I weredeleced. binding between the
two proteins did DOl occur. BAG-l was also found to increase the level of HOF-mediated
protection from apoptosis induced by staurosporine and etoposide in mouse Jivercclls. BAG-
I by itself could not confer resistance to these drugs however. To assess whether BAG-I
could influence the antiapoplotic properties of related receptors, platelet derived growth
factor (pDGF) and epidennal growth factoe" were added 10 cells in the presence and absence
BAG-I. BAG-I iocreasod the prolecrion by P[)GF to staurosporin-induccd apoptosis and it
was subsequently found that BAG-) could bind to the PDGFR as well. Interestingly, the
whole length oftheir mouse BAG-I done (COlTeSpOnding approximately to the 33 IDa foan
of human BAG-I) was nccdcd forcoope:r.ttive prevention ofapoptosis with the HGFR and
PDGFR. not just the BAG-l C-tenninus, which asmentionc:d earlier, is necessary rorBAG-1
to bind to BCL-2 orRAF-l. This may point towards BAG-I acting as a bridge linking the
HGFR and PDGFR to other proteins which then transmit the antiapoptotic signal from the
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cell membrane to the innercelJ,OI"BAG-t itselfmaymove from therecc:ptors 10 transmit the
cell survival signal. The fact that BAG·I is not phosphorylated by tbcsc receptors (Bardelli
et al., 1996) suggests that it may act as some type of linker molecule, since theR. swvival
signals are often conveyed by signalling cascades (RousseI1998). It is possible that BAG-l
transmits a survival signal from these receptors through some as yet undiscovered
mechanism to BCL--2. which then elicits a survival response.
It is reasonable to expect that abemmt expI'CSSioo of a receptor, such as the HGFR.
lhal is tightly linked with prolifmltion, may result in tumorigenesis. This hypothesis has
been proven correct and high levels of HGFR have been linked to several types ofcancer
including thyroid carcinoma (Oi Renzo el at., 1992). sevenl types of sarcoma (Rang et aJ.,
1993), and liver cancer (Boix el aJ., 1994). These studies have been supported by in vitro
studies showing that overexpression of HGFR in mesenchymal cells results in increased
rumorigeoic and metastatic potential of the ceUs (Taybet, all998).lfBAG-1 is an integral
member oflhe HGFR pathway, its ovc:rexpression could result in the constitutive activation
of the pathwaY,leading to increased prolifer.Jtion and potential tumorigenesis.
1.2.2.4 Steroid bormo.e re«pton
Steroid hormone receptors are key elements in the endocrine signal transduction
pathway. Mcmbcn; of this superfamily include the glucocorticoid, thyroid, estrogen,
androgen. progesterone, rctinoic acid, mineralocorticoid and vitamin D receptors. This
family of receptors are intracellular tnlnscription factors having similar structures, but
eliciting a broad spectrum of cellular responses. Thcy are all modular in structure, having
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domains involved in dimerization. protein-protein interactions and a zinc finger DNA
binding domain (LundCCD et al., 1996). The receptors elicit a cellular responsc: wbea
activated bybonnooes by binding 10 a specific sequence orONA called a hormone response
clement in promoter" region ofa specified gene and tbcrcby rqulate the rate oftranseription
of the gene (Beato 1989). Regulation of transcription by hormone receptors involves
chromatin remodeling ( Fryer- and Arcbet" 1998). cross talk with other ttanseriptioo (aclon
(Heck et al., 1994) and interaction with the basal transcription machinery through binding
to TFIIB or TFIID. Binding of the hormone receptors to these transcription factors can be
either direct (Baruahmad el al., 1993, McDonald el oJ., 1995) or indirect through
coaclivalor/corepressor proteins (Goodrich er 01., 1996; Wong and Privabky 1998).
II was first reponed by Zeincrand Gehring (l99S) that human BAG-l could interact
with members of the steroid receptor family, including the glucocorticoid, estrogen,
androgen and progesterone receptors in vitro, but no functional analysis was perl"onncd..
Since then, a number ofsrudies have investigated the interaction between BAG-I and these
receptors and the ability of BAG-l to modulate the function of the receptors.
1.2.2.4. GI.cocortkoicl receptor
Glucocorticoid receptors (GR) are found in almost all human cell types. In
accordance with this observation, glucocorticoids have a number orvaricd nonnal functions
in humans, including, among othen., gluconeogenesis (thus regulating blood sugar levels)
(Scott el aJ., 1998), prolein catabolism (Louard el oJ., 1994), anti.innamrnatory actions
including lowering the number" of most leukocytes (lymphocytes, eosinophils, elc.) via
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apoptosis (Calo and Wade 1996}, and protection against mental stress (Munc.k and Tom
1994). With all their physiologicaJ. effects. it is not surprising that the glucocorticoid
hormones are necessary to sustain life.
Most of the actions ofglueocorticoids are mediated by the binding oftbc hormone
10 its reccptOf", which results in the release of inhibitory heat shock proteins from the
receptor, and allows it to bind to a specific glucocorticoid response element (GRE) in a
target gene. The: GR may up or down regulate gene expression, depending on its intenc:tion
with other transcription factors. such as the JunlFos AP-I complex (Minal et 01., 1994; lana!
et a/.. 1990) and NF-KB (McKay and Cidlowslti 1999).
Because of the previously reported ability of BAGp46 to interact with the GR
Kullman et al., (1998) investigated whether BAGp46 had any affect on glucocorticoid
mediated apoptosis or transcriptional transaetivation. The researchers found that BAG-l
could rc:pressSQ-/oofthctransaetivationbythcGR in hWtwtJEG-J and mouseS49.1 cells
oreAT reportes"construets containing GREs. IntCf'CStingly. it wasnotcd that BAGp46bad
no effect on the ability of the androgen receplOf" (AR) to activate transcription through its
response clemellt. Furthermore. it was found that overupres.sion ef BAG-I could block.
glucocorticoid-induced apopcosis in S49.1 cells. Finally, the researchers demonstrated that
BAG-I could inhibit the DNA binding activicy efthe OR. It was found, using electrophoretic
mobility shift assays (EMSAs), that lhe OR DNA binding was absent in cell extracts from
simian COS·7 cells transfccted with BAGp46. These results show that BAG-lp46 is a direct
inhibitor ofGR action. This is interesting because even though glucoconicoids can induce
apoptosis in almost all lymphocyte types, they inhibit apoptosis in neulrophils (Kate et at.,
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1995) and in mouse mammary glands (Feng et af., 1995). Therefore. it would stand to reason
that BAG-I, by interfering with GR action, may have opposing fimctions in different cell
types. It was not demol1Strated that BAG-I could control GR-mediated tnlns3ctivation orallY
orits effector genes.
Glucocorticoids are currently used to treat several types ofcancer, including multiple
myeloma (Gieseler and Nussler 1998) and leukemia (Kaspers el af., 1994). By inhibiting the
binding ofthe GR to DNA. it is possible that ovcrexpression of BAG-l may be contributing
to inhibition ofapoptosis in leukocytes and drug resistance in some cancers. This lends more
evidence to BAG-I being a potential oncogene.
1.2.2.4b Aadrogea receptor
Androgens are a family ofhonnones (including testosterone) produced primarily in
the testis. As with most honnones, they have a broad range of functions such as aiding in
sperm maturation, nonnal growth of the prostate gland. maintaining secondary male
characteristics (deep tone ofvoice, for example) and increasing muscle mass, etc. Similar to
their glucocorticoid cousins, androgens exert their effect by activating the AR,. allowing it
to bind to a specific androgen response element and thus regulate gene expression. The AR
is found in most tissue types and has been found to both inhibit (Zatelli et aI., 1998) and
promote (Lin et al., 1998) cell proliferation, depending on the cell type. The exact genes
involved in androgen-mediated cell proliferation or arrest are still largely unknown. Only
gene products seemingly unn:lated to cell growth, such as ornithine decarboxylase (pajunen
et aI., 1982) have been discovered at present.
"
Because ofBAG·!'s interaction with the AR (Zeiner and Gehring 1995), Froesch el
aI., (1998) decided to further examine lbc relationship between the two proteins. These
researchers showed that the AR can co-immunoprecipitatc with BAGpSO, but nol the shorter
isofonns. It was also shown that BAGpSO can significanlly heighten the activation orCAT
reporter constructs containing AR response elements when colnlnsfected with the receptor
in several cell types, while the p46 isoform had little or no effect. This is consistent with the
observation of Kullman et al.• (1998), who demonstrated that BAGp46 had no affect on
androgen-mediated transcription. In addition, BAGpSO could markedly decrease the ability
of antiandrogens to inhibit transactivation oreAT activity by the AR.
Cancer of the prostale is intricately linked to androgens (Culig et al., 1998 and
Visakorpi el aJ., 1995) and both the overexpression aCthe AR and mutations ofthe AR have
been linked to male breast cancer (Lobaccaro et ai., 1993, Hiort el al., 1996). In both types
ofmalignancy, anti-androgens are conunonly used in therapy (Newling 1998, Doberauer et
01., 1988). However, il is common for honnone-dependenl tumors to progress into a largely
untreatable honnone-independent slate (Crawford et al., 1989). It is possible thai,
overexpression ofBAGp50 in Ihe course oftumor progression could enhance AR-mediated
proliferation and impede anti-honnone Iherapies. It would be interesting 10 sludy Ihe
expression of BAG·1 in honnone-dependent and independent prostate tumors.
1.2.2.4c RedDole add receplor
Retinoic acid is a naturally occurring, active metabolile of vitamin A. It is involved
in a plethora ofessenliallife processes (Mangelsdorf et al., 1994) including bone resorption,
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cell differentiation and normal embryogenesis. It also affects reproduction. in that it increases
the production of testosterone . Retinoic acid is responsible for regulating such genes as p68
kinase (pelicano et a/., 1997), Egr-I, which is involved in cell growth and differentiation
(Larsen et af., 1994) and the cell cycle regulator p21 wafl (Liu et al., 1996). The retinoic acid
receptor (RAR) is functionally the most complicated of the steroid receptors. It has three
subtypes (<<,Il,Y) and its gene activating specificity is partially determined by the
heterodimen it forms with the retinoid x.. vitamin D and thyroid receptors (Garcia-Villalba
et al., 1996). As well, its function is modulated, like other honnone receptors, by a large
number of cofactors.
Because of its interaction with other steroid receptors, Liu et al., (1998) thought that
RAR-IX would be a promising candidate as another BAG-I binding protein. The researchers
found, using GST-fusion proteins, that BAGp33 could interact with the retinoic acid receptor
but not with the retinoid X receptor (RXR). This interaction was nol negated by deleting the
last 47 amino acids from BAG-I '5 C-tenninai. indicating that this region of the carboxyl
tenninal a-helical domain is not required for their binding. The proteins were also shown to
interaci using the yeast two-hybrid system. To test the functional significance of the BAG-I-
RAR interaction, BAG-I and RAR wen:cotransfected into monkey CV-l cells with CAT
constructs containing RAR response elements. It was found that BAG-I could inhibit RAR-
mediated transactivation. In addition, the researchers also noted that BAG-! could inhibit
thyroid honnone reaptor uansactivation through its response element. Similar to the work
performed by Kullman et at., (1998) with the GR, these investigators found that BAG-I
could inhibit the binding of the RAR, RARJRXR heterodimer and thyroid receptor to their
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respective response elements. It could not. however, inhibit the DNA binding ability of the
RXRmonomCl".
RA is Icnown to inhJbit the proliferation ofbrcast cmcercells (Ucda et 01., 1980). The
researchers next explored whether or not BAG-I could interfere with RA-mcdiatod growth
inhibition in MCF·' and ZR-7S breast cancer cells. They found that BAG· I could reduce
RA-induced growth inhibition in MCF-1 cells by 35% and ZR-7S cells by 25%. Because RA
is also known 10 induce apoptosis in both ofthesc celliincs (ScewakitetaJ.. 1995) they next
investigated whether BA(}.1 could inhibit RA-induccd apoptosis in these cells. BAG-I
could inhibit RA induced apoptosis by 26% in ZR·7S cells but oot alaIl in MCF-7 cells. In
addition. it was found that overexpression of BAG-! could prevent inhibition of BCL-2
expression by RA in MCF·7 cells. lbcse results indicate thaI SAG-I may be an important
and novel regulatOl" ofthe retinoic acid hormone pathway.
RA is currently being used to treat epithelial tumors and promyclocytic leukemia
(Alberts and Garcia 1995). Again. irBAG-l expression were to become upregulaled in an
uncontrolled fashion, these cancer cells may also become resistant 10 chemotherapy. Thne
have been no studies at the present which examined the expression or BAG·l in drug
resistant cancers.
1.1.1.5 Heat sllock proldas
How can BAG·I intcncc with 50 many proteins? One possible answer is through its
interaction with heat shock protein 10 (hsp10) (Hohfeld and Jentsch 1991, Zeiner et aJ.,
1991, Takayama et af., 1991). Heat shock proteins comprise a large ramily or ubiquitous
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proteins that are necessary for the folding of many proteins into their native confonnation
(referred 10 as chaperone activity) as well as uanslocating proteins across intracellular
membranes, including nuclear translocation (Bukau and Horwich 1998). Hsp70 is known to
bind theGR(Hutchisonetal., 1994) andRAF·l (Hutchison et aJ.. 1993). Therefore. BAG-I
may interact with these proteins indirectly through hsp70. Zeiner et of., (1991) demonstrated
that BAGp46 could indeed bind to a number of unidentified proteins indirectly through
hsp70. The chaperone activity ofhsps involves a hetenxomplex ofdifferent hsps. including
the hsp90 and 70, among others (Czarel aI., 1994). This may mean that, even though hsp70
isn't directly involved in binding to theAR or RAR. BAG·) may bind indirectly to these
receptors through hsp70's interaction with the hsp90 which does bind directly 10 them.
Three very similar papers were published in 1997 describing the internction between
BAG-! and hsp70 (Takayama el al., 1997, Zeinerel 01., 1997, Hohfeld and Jentsch 1997).
Hohfeld and Jentsch (1997) docwnented the binding ofmousc BAG-I to the ATPasc domain
ofhsp70. This binding stimulated the release ofADP from hsp70 and subsequently promoted
the formation of the ATP-bound form ofhsp70. Zeiner el of., (1997) demonstrated that
BAGp46 could bind in vivo to the ATPase domain of hsp70 and could inhibit hsp7()'
mediated protein folding in vitro. Similarily, Takayama elaf., (1997) showed that BAG-I
could bind to hsp70 in vivo. could inhibit hsp7o-mediated protein folding in vitro and (in at
least one human cell line. if overexpressed) could protect cells from heat shock induced
apoptosis.
The hydrolysis of ATP is known to be importam for the binding ofproteins by hsp70
(Szabo el al., 1994). The ADP bowtd fonn ofhsp70 can fonn a heterocomplex with binding
Table 1.1 BAC-llntrudlllC protrlal
BAG-I inlmctinR orotei Effect of intmclion SilmirtcarlCe
BCL-2 I Enhan<:cs abilily of BCL·2 10 inhibil IOvel'tllpression ofBAO-1 Of BCL-2 may enhance
lpoptosis the 1umoriatnM: potentia' ofttlc ocher
RAF·I I Enhances kinase potentill ofRlf·1 I Ovcrexprusion of BAG-I could kIId toconstilutive
IIttivalion of the RAF·I,plthw.y resulling in
unconlrollcd cell growth
HOF. PDGF I BAG-I enhances IrIli·apoplOlie lbility of IHigh levels of BAG-I coukt il'lCl'UIC proliferative Of
both prolcins Inti-apoptOlic polenlill ofpathw.y ICidinglo cell
tumorigCllk:ity
GlueOCOl1icoid rtCcptOf I BAG-I inhibitsGR DNA binding and IMIY be involved in resislance 10 glOCOCOlttcoid
glUCOCOJ1icoid induced apopcosis hormone thenpy
Androgen rcccptOf I BAG-I enhanceJ AR·medilled transcripCion I MIY enhance Ibility of AR to transform prosIlte celli
Rctinoic acid rtCeptor I BAG-I inhibil5 RAR DNA binding and minoicl M.y intCff~ wilh ability ofRA to treat leukemia
acid·mediated proliferation and apopIosis,,,
well as blocking the ahility ofRA 10 decrease
BCl·2ellprtssion
Hcat shock protein 70 I Involved in hsp70 ATP hydrolysis. Induces
hsp70 to release bound proteins. Prevents
hsp70 mediated protein folding.
May be involved in hsp7Q.medi.ted inhibition of
apoplosis. May act on a variety ofproteins through
intmction with Hsp70
:0
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partners, while the ATP-bound Conn cannot. Taken together, these studies indicate that
BAG-} promotes the release ofhsp70-bound proteins by stimulating the ATP bound state
ofhsp70. This cripples the protein folding abilityofhsp70. because it cannot remain bound
to target proteins. It is also possible that the function of BAG-I in vivo is to stimulate the
release ofhsp7o.bound proteins when proper folding has been achieved.
The two repons showing that BAG-l can inhibit hsp70-mcdiated protein folding are
somewhat confusing because hsp70 is known 10 have anti-apoptotic properties (Gabai et a/.,
1995) and may play a role in tumorigenesis (Kaur and Ralhan 1995; Ralhan el al., 1995 and
Jaattela 1995). Therefore. it seems contradictory that BAG-I should inhibit bsp function,
since this would implicate BAG-I in functions opposite to those previously mentioned (that
is, being pro-apoptotic instead ofanti-apoptotic). However, it is certainly possible that the
interaction between the two proteins is necessary for purposes other than those involved in
apoptosis. This hypothesis is supported by the wide range ofcellular roles in which lhe hsps
are involved. However, it is still unknown which particular functions are necessary for its
ability to inhibit apoptosis. Funhemtore, it has recently been shown lhat hsp10 exerts its
antiapoptotic effocts downstream ofcaspase activity (Jaanela el at., 1998), whereas BAG-I
(as mentioned above) acts upstream ofcaspases (Schulz et at., 1997). Therefore, BAG-I and
hsp10 may act at different steps in lhe same palhway and lheir binding may function to
COlUloct different steps in lhe signal transduction pathway. In addition, it may be possible that
different isoforms ofBAG-I have different effects on hsp1Q-medialed folding and may work
wilh hsp10 10 release proteins having achieved proper folding or, conversely, inhibitlhe
folding of pro-apoptotic proteins. At lhis time, the effect of BAGp50 on hsp1O-mediated
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folded is unknown, as is the precise physiological relevance ofBAG-l's interaction with
hsp70.
1.3 Furtller evideau impUcatiag BAG-l as. mmorlgok protei.
Cells thai have achieved a growth faclor-independent stale consistently have
enhanced cell survival capabilities. Growth factor independence has also been shown to
result in increased tumorigenic cell potential (piao et aJ., 1996 and Howard el al., 1996).
Clevenger et ai" (1997) demonstrated thaI overexpression of murine BAG· I in the
IL-3-dependent ce111ine BalF3 could confer IL-3-iodependence on the cells. It was also
found that the addition of JL.J to BalF3 cells increased BAG-I protein expression,
suggesting that BAG-I is involved in the survival and growth ofthese cells. It was nol shown
however, whether BAG-I-induced growth factor-independence could enhance cell
tumorigenicity.
There have been several recent studies investigating the status of BAG-I protein in
various tumor types and tumor cell lines. BAG-l has been shown to be expressed at higheT
levels in lung, breast and cervical twnorcelllines (Takayama et al., 1998 Yang el aI., 1998
b,c Zapata et al., 1998) than their non-twnor counterparts, as well as in 40"/0 of breast
can:inomas jn situ and invasive breast cancers in one study (Zapata et aJ., 1998). In addition,
studies have shown that BAG-I is expressed at higher levels in human papilloma vinas-
transfonned endocervical cell lines than non-transfonned cells (Yang et af., 1998 a,b). One
study (Yang et af., 1999a) also demonstrated that BAG-I is present at much higher levels in
cervicailumOrs than nonnal cervical tissue. In addition, it was found that overexpression of
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BAG-l correlated with resistance to Slaurosporine-induced apoptosis in cervical ccUs.
Zapata et al., (1998) have shown that BAGp33 is the most prevalent isoform. in the
breast tumors they've studied. while Yang et al., (l998b) have found all isofonns
overexpresscd in many different types of cancer cell lines. All the data collected thus far
supports the hypothesis thai BAG·t is involved in tumorigenesis.
1.4 l,25-dibydroxyvitamia DJ (1,25-vltamJa 03) aad tke vitamJa 03 receptor
As previously mentioned., BAG-I can interact with a variety of steroid honnone
receptors. Another member of the steroid hormone superfamily, with links to cancer, is the
I,2S-vitamin 03 receptor (VDR). The primary physiological rote of 1,25.vitamin D3 (the
active metabolite ofvitamin 0) is maintenance of serwn calciwn levels. It regulates the level
of calcium in the blood by increasing intestinal absorption of calcium and resorption of
calcium from bonc. 1,25-vitamin 03 is also involved in bone remodeling (Haussler et aJ.,
1997). 1,25-vitamin 03 maintains calcium homeostasis through the regulation ofgenes such
as osteocalcin, ostcopontin and calbindin (Lian and Stein 1992). Like other steroid
hormones, 1,2S-vitamin 03 elicits a celiulliT~ through activation ofits receptor which
then regulates gene transcription through a specific vitamin 0 response element (YORE).
The YORE consists of a direct hexanuclcotide repeat separaled by three random nudcolides
(Lian and Stein 1992).The consensus YORE sequence is as follows:
AGGTCANNNAGGTCA Once the VDR is activaled by its ligand, it undergoes a
conformational change. binds the retinoid X receptor (RXR) and binds VDREs as a
heterodimerdimer (Strugnell and Deluca 1997). A number of accessory factors are also
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involved in VDR-mcdiated tr.u1SCriptional control, such as SRC-I, RIPI40 (Masuyama et
aJ., 1997) and GRIPI (HoolnaJ.• 1997). 'The VDR is believed to mediate transcription
through its direct intenction with TFIIB (MacDonald ef aJ., 1995).
TIle VDR has also been shown to bind several VDREs as a homodimer (Nishikawa
eJ aJ., 1994 and Pollyer 01., 1996). In addition. it has been reported that the VDR can bind
DNA as a homodimc:r indepcndently of ligand activation (Matkovits and Christakos 1995).
Then: bas been much discussion on the significance afthe VDR bomodimer in villa. Some
researchers believe that the homodimer has in villO significaoce based OD the fact that CAT
constructs containing YOREs lhal arc bound specifically by VDR homodimeno can be
activated by l,2S-vitamin 03 (Carlberg et a/., 1994), while others suggest that the VDR
homodimer serves as a negative regulator of transcription (Mackey et aI., 1996). Other
researchers claim that it is only found in ;11 vitro experiments (Haussleso et aJ., 1997).
However. the matter remains inc:onclusive. Doe theory hypothesizes that the VDR exists as
homodimerwhen not stimulated by l.25-vitamin 03. This homodimer can bind 10 a YORE
in the absence of ligand and may actually~themcoftranseriprion. But once stimulated
with ligand. heterodimeriu.tion with the RXR occurs and it subsequently upregulates
transcription of the same promoter (Cbeslcis and Freedman 1994). However, other
researchers have found thai the sequence of the YORE is essential in determining which
dimerized fonn of the VDR will bind (Nishikawa et 01., 1994; Mackey et 01., 1996). In
addilion il as been found thai the binding ofVOR as a homodimermay result in an increase
in transcription of selected genes (polly et oJ., 1996; Kahlen and Carlberg 1994). VDR-
mediated lranscription is obviously a very complicated process and much more work is
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needed before it is completely understood.
The VDR is localized in the cell nucleus. Related to this. is the fact that the VDR is
the only steroid honnone receptor not known to bind hsps (Whitfield el al., 1995). Hsps, in
addition to being responsible for proper folding of steroid receptors, are known 10 bind and
sequester honnone receptors, such as lhe GR., in the cytoplasm until they become honnone
bound, al which time they are released from hsps and move into the nucleus.
Even though the primary function of I,2S-vitamin 03 appears to be maintaining
calciwn homeostasis, the VDR has been found in a wide range ofcells including leukocytes,
neurons. and ovarian cells. This indicates that 1,25-vitamin 03 may have diverse functioDS.
One of theses functions may be the induction ofdifferentiation in various cell types (Abe
el aJ., 1981; Bikle et a/. , 1988). Another may be the regulation ofeel! proliferation (Lemire
et 01., 1984; Clohisy et af., 1987; Casado ct et 1998).
In addition 10 regulating the proliferation ofnonnal cell typeS, researchers have found
that 1,25·vitamin 03 can inhibit the growth ofcancer cells both in vivo and in vitro through
inhibition of proliferation and induction ofapoptosis (Eisman et et 1987; Dokoh et al; 1984,
Simboli-Campbell elal., 1996). 1,2S-vitamin 03 may accomplish these functions through
the regulation of genes, such as p21-n (Liu el aJ., 1996), BCL·2 (Xu et aJ., 1993)and c-myc
(Reitsma et al., 1983). However, clinical studies have shown that hypercalcemic effects of
1,2S-vitamin 03 make this type of honnonal therapy impractical (Blazek. el oJ., 1992).
Recently, new vitamin 0 analogs have been developed that have potential for cancer therapy
because of lowered hypercalcemic effects and greater apoplotic potential (Abe el 0.1., 1991;
Van Weelden el a/., 1998).
2'
1.5 The CeU Cycle ID.ibltor pZI"'"
One of the genes containing a YORE is p2l Wl1n ,It is believed that one potential
mechanism of l.2S-vitamin D3-mediated inhibition ofproliferation is through uprcgulation
ofp21...rtranscription (Liu eJ aJ., 1996c). p21 wafl is a cell growth-regulating protein that can
block cell proliferation by inducing cell cycle arrest at the Gl phase. It accomplishes this
through binding and inhibiting cyclin.dependent kinase-2 (CDK2) which is an activator of
several cell cycle promoting proteins called cyetins (Harper et al., 1993). p21 wafl can also
inhibit cell cycle progression through inhibition ofprolifen.ting cell nuclear antigen (PeNA).
which is involved in DNA replication (Chuang et al., 1997). [n tum, several regulators of
proliferation regulate the transcription ofp21 wafl , including l,2S-vitamin 03 (Liu et 01.,
1996:), RA (Liu et al., 1996b), SmadJ (Moustakas and Kardassis 1998) and pS3 (cl-Diery
ela/..1993).
Even though studies show that p21 waf1 , like pS3, can suppress tumor growth in nude
mice implants (Chen el aI., 1995), there have been few studies which point lowards
deregulation or mutation of p21-n being a major factor in human twnor fonnalion (Cox
1997; Nakayama and Nakayama 1998). This is most probably due to overlapping pathways.
However, some studies have indicated that the tumor suppressing potential ofp21-n may
make it a suitable candidate for gene therapy (Chen et at 1996).
1.6 Objective ohbls study
Based on the previous findings that BAG-I can bind and regulate the function of the
AR, GR, and RAR, it seems that an importanl function of BAG-I is 10 regulate steroid
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hormone pathways. 1bc objective of my study was to further characterize the role ofBAG-I
in steroid hormone receptor regulation by investigating if BAG-I could bind and modulate
the function ofthe VDR. We are particularly interested in the VDR because I ,2S-vitanrin 03
analogs arc currently being developed as potential cancer therapies and the levels ofVOR
coaclivators and corepressors may play an important role in detemtining whether a tumor is
receptive or resistant to these new chemotherapies. In addition, ifBAG·1 does exen an effect
on the VDR, can BAG-I effect 1,25-vitamin D3-mediated transcriptional transactivation of
VDR target genes?
To achieve these objectives, Far Western blotting and GST·fusion protein pull-down
analysis will be utilized to determine ifBAG-I binds the VCR.. Cells stably transfected with
BAG-l will also be employed to determine ifBAG-1 has any effect on the following; 1) the
DNA binding ability of the VDR 2) VDR mediated tr.mscriptional transactivation 3) 1,25-
vitamin D3-mediated inhibition of proliferation.
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CIlAP'ttRl
MATERIALS AND METHODS
1.1 CeU c.lrue
Hum.m US7 MG glioblastoma and C33A cervical carcinoma cells wcr-e grown in
Dulbccco's modified Eagles medium (DMEM) (Gibco BRL) supplemented with 10";' fetal
bovine senun and 1% penicil1infstreptomycin. Confluent cells were detached from the plate
using trypsin-EDTA (Gibco DRL) and passed 1:10 into new plates. Cell counts were
perfonned using a bemocytomder (Fiscber).
1.1 PlaSllllds
Plasmids were prepared by a cesium chloride gradient method, as described by
Sambrook et 01., (1989). The pSO and p46 isoforms of BAG-l (Yang et oJ., 1998b) were
contained in the EcoRI site oCthe expression vector pa3.1 (Invitrogen). The VDR eDNA
in plasmid pCMX was a generous giR of Dr. Ronald Evans (Umesono et al., 1991). The
p21-n promoter/enhancer region contained in the lucifenue reporter plasmid PGU was a
gift of Dr. Ben. Vogelstei.n (el-Deily n oJ., 1993). The p21 promoter/enhancer" in the
luciferase reporter-plasmid wwP (p21-4) was a generous gift of Dr. Wafik EI-Deiry (Zeng
et al., 1997). Plasmid VDRElkCAT conlaining multiple copies ofthe osteoca.lcin VDRE was
a gift ofDr. Sylvia OuiSlakos~..alkovitsand Ouistakos 1995). The ~plactosidasereponer
plasmid PCHIIO was purchased from Pharmacia Biotech. 1be lucirerasc rcporterplasmid
POL) was purchased from Invitrogen.
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2.3 Calcium p"ospllate-medllted traasfudoa.
This protlXol was perfonncd with little variation from the method described by Chen
and Okayama (l987). Cells were grown to 70010 confluence and medium was changed 30
minutes prior to transfection. 2-3 Ilg DNA/mt of DMEM, 10 IJ.I filter sterilized 0.25 M
CaCllml DMEM and distilled H20 were mixed in a final volume of 100 J.ll/mi DMEM.
Then, an equal volume of filter sterilized 2X BDS pH 6.96 (50 mM N,N-bis[2-
hydro~yIJ-2-amino-ethanesulfon.icacid, 280 mM sodium chloride, and 1.5 mM sodium
phosphate) was added. This mixture was then left at room ternperarure for 13 minutes after
which it was added dropwise to the plates and the plates gently swirled.
Transfected cells were incubated in a 3% COl incubator for 16-24 hours. The cells
were washed with PBS, fresh medium added and the ceUs incubated in 5%~ for a fiuther
48 hours.
2.4 Stable traas(ectio.s
US? cells were seeded in 24-well plates at a density of 0.5 X 10' cells/well. Cells
were then grown in the presence of varying amounts ofG418 (Gibco-BRL) to detennine the
concentration ofthe drug necessary to kill all ofthe cells in 4-5 days. For this particular cell
line, 750 )1g/ml of media was delcmrined to be the lowest concentration ofdrug necessary
to kill all the cells in a 5 day period.
US7 cells were next subcultured 1;12 from a lOcm plate 10 a single well ofa6 well
plate. The cells were next transfocted by calcium phosphate precipitation with 5 )1g BAGp50
or its parent vector per3.l. At 72 hours post.transfection. the cells were subcultured into three
2'
10 em plates and grown in the presence of 750 j.1g1ml G418 for 14 days. On day 14, well
separated colonies were transferred to 96-well plates. The cells were continued to be grown
in the presence of 0418 and transferred 10 24-well and then 6-well plates as they became
confluent until enough cells were present for DNA or protein preparation.
2.5 RNA ntt.elio.
RNA was extracted from cells using a cesium chloride gradient method, as described
previously by Sambrook et 01., (1989). Generally, RNA was collected from fourplales of
80% confluent cells. Cells were washed with phosphate buffered saline (PBS) (154 mM
sodium chloride, 1.54 mM potassium dibydrogen onhophosphatc and 2.71 mM sodium
phosphate) and 1.8 ml of lysis solution (4 M guanidine isothiocyanate. 17 mM sodium N·
lauroylsarcosine, 8.5 mM sodium citrate pH 7.0 and 53.5 ",I mercaptoethanoVI.8 ml total
lysis volume) in diethyl pyrocarbonate (DEPC)-tteated watct" ( add 4 ml of DEPC 10 4 liters
water. cover top with foil, place in 45°C water bath overnight and autoclave) was added to
each plate. Plates were scraped with a robber policeman, the lysate transferred to another
plate using a 10 ml syringe with a 20 gauge needle and the process repeated using cells from
all other plates. For the final plate, the combined Iysates were passed 10 times through the
needle and carefully overlain onto 3.5 ml of a cesium chloride solution (5.7 M cesium
chloride and 100 mM ethylenediamine-tetraacetic acid (EDTA) made up in DEPC treated
water) in a Beckman SW4 I tube (also DEPC treated). The tubes were then balanced using
lysis buffer and centrifuged at 30,000 rpm for 20 hours at 22OC. After centrifugation, the
supernatants were decanted and the pellets were air-dried for to-30 minutes. The pellets were
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subsequently dissolved in 200 ~I DEPC treated water, tnmsferred to DEPC treated 1.5 mt
Eppendorftubes, the SW41 tubes were rinsed with an additional 200 }LI water which was
also added to the Eppendorftube. Next. 40 pI 3M sodium acetate and 880 1J.1 100"/0 ethanol
were added to the tubes to precipitate the RNA. Tubes wen::: placed in -7frC for at least two
hours (can be left overnight). Next, the tubes were spun in a microcentrifuge at 4"<: for 1S
minutes, the supernatants aspirated after which the pellets were washed in ice cold 70"/0
ethanol and respun. The supernatants were again aspirated and the pellets allowed to air-dry
for 5 minutes followed. by S minutes in a vacuum. The RNA pellets were reconstituted in
DEPC·tn:ated water (usually 25-50 pi) and stored at -,()'>C.
2.6 Nortbera blots
Northern blots were perfonned as described by Sambrook et aJ., (1989), with several
modifications. Gel electrophoresis equipment was soaked in 0.1 M sodium hydroxide for IS
minutes to prevent RNase contamination and then washed with DEPC-treated water. RNA
was resolved on a 1% agarosclformaldehyde denaturing gel (4 g agarose, 40 mllOX 3.[N-
Morpholino]propanesulfonic acid (MOPS) buffer (0.2M MOPS, 0.05 M sodium acetate pH
7.0,0.1 M EDTAin DEPC treated water) 21 ml fonnaldehydemadeuptoa final volume of
400 ml with DEPC treated water). 20 ~goftota1RNA was adjusted toa final volume of11.2
J.11 with DEPC-trealed water. 20J.11 fonnamide, 4 ~I lOX MOPS and 4.8 f.ll formaldehyde
were added to the RNA, the solution mixed and subsequently denatured at 65"C for 15
minutes and chilled on ice for 5 minutes. 4 J.11 of gel loading buffer (50% glycerol, ImM
EDTA pH 8.0, 0.25% bromophenol blue, 0.25% xylene cyanol) was added to each sample.
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After loading,the gel was run at 3S volts overnight in IX MOPS buffer.
The RNA was next transferred from the gel to a nylon membrane by capillary
transfer. A glass tray was filled with 20X sse (3 M NaCl, 0.3 M trisodium citr.lte). A glass
plate was placed across the tray to use as a platfonn. A wick, composed of two pieces of
Whattnan 3MM filter paper saturated with 20 X sse, was placed across the platfonn and
into the 20X SSe. The gel was placed on the wick., being careful to avoid trapping any air
bubbles under the gel. A piece orDylon membrane (Hybond.N, Amersham) cut to the size
aCthe gel, was placed on the gel again being careful to avoid trapping any bubbles. lfbubbles
appeared. they were removed by rolling with a pipette. The edge of the gel was surrounded
with Saran wrap to prevent dispersion of the buffer. Three sheets ofWhatman 3MM filter
paper wetted with 20X sse were placed on top oftbe membrane. Finally. a stack ofpaper
towels (approximately 5 em high) was placed on top of the membrane with a 0.75 • I kg
weight in tum being positioned on top ofthc paper towels. Transfer was allowed to proceed
overnight.
The RNA was next fixed on the membrane by baking the membrane at 8O"C for 1.5
hours followed by exposure 10 UV light (254 nm) for 3 minutes.
Blots were prehybridized at 65"C in QuickHyb buffer (Amersham) for a minimum
of 10 minutes in a sealed plastic bag, at which time a cDNA probe was added. Probes were
prepared using the Rediprime labeling kit (Amersham). Briefly, 25·50 ",g eDNA in 40 ",I
water was boiled for 5 minutes after which it was added, along with 5 loll [a:_p32]-dCTP 10 a
lube of reaction mix. The reaction is allowed to proceed at 37"C for 20-30 minutes after
which the probe was purified using a Nick column (phannacia) as recommended by the
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manufacturer.
Hybridization buffer (2 X 10'" cpm probefml) was mixed with I mg salmon sperm
DNA per 10m! hybridization buffer and boiled for 5 minutes. afterwhich it was immediately
chilled on icc for 5 minutes before being added to the membraDC. lbe probe was iocubaled
with rocking at 6S"C with the membnoe for two houn. Membranes were then wasbcd twice
for I S minutes al room ternpenturc in 2X SSe. 0.1 % 50dium dodecyl sulfate (50S) and
twice for 15 minutes at SO- 6S-c (depending on the specificity of the probe) in O.IX sse,
0.1% 50S. After wa.shing. the membrane was wrapped in plastic wrap and exposed to Kodak
Biomax film at -7O"C.
2.7 CeU enracts for laiC expressio. assays
Cell extracts were prepared according to the method ofGonnan eJ aJ., (1982). The
cells were scnpc:d from the plates with a rubber policeman, spun for I ntinutc in a
microccntrifugc and resuspended in 0.25 M Tris buffer (tris(hydroxymethyIJ·aminomethanc)
pH 7.8. Suspensions wer'e stored at ·7f/"C or were used immediately to pn:pareccU extr.ICtS.
Cell extracts were obtained v;a thn::c frecze..tbaw cycles of S minutes each in liquid nitrogen
and a 37"C watcrbath, respectively. The lysed cells wen: chilled on ice for 10 minutcs and
spun for S minules at 4"C in a microcentrifugc. Supernatants was collected and stored at •
7O"C until it was to be used for chloramphenicol acetyl transferase (CAn, J}-galactosidase
or luciferase assays.
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2.8 CAT assays
CAT assays were perfonncd as originally described by Gonnan etal., (1982). 10 pi
cell extract was mixed with 20.,a1 CAT reaction buffer (4 III of4 mglmJ acetyl coenzyme A.
1 III [1·C]-labeledchJoramphenicol (I Jlci), I III water and 14111 ofl MTris buffer pH 7.8)
and incubated for I hour. To stop the reactions and isolate the chloramphenicol reaction
products, SOO JlI ethyl acetate was added to the reaction. tubes were vortexed and
microccntrifuged for 1 minute. The supernatant (organic layer) was collected. put into
another eppendorftube and placed into a speed vacuum (Savant) until the ethyl acetate was
completelyevaporated. Pellets were dissolved in IS loll acetyl acetate and sponed on a thin
layer chromatography (TLC) sheet (Kodak). The acetylated and non-acetylaled
chloramphenicol products were separated by ascending chromatography in
chloroform:methanol (95:5). The TLC plates were then exposed to Kodak film overnight at
room temperature. The percentage of acetylaled chloramphenicol was subsequently
quantitated by densitometry using the Cyclone phospho-imaging system (CanberTa Packard).
All CAT and luciferase assays were perfonned at leasllhree times.
2.9 P-Galactosldase assay
P-gaIatosidase expression assays were perfonned as a control for CAT and luciferase
assays, as recommended by Pharmacia Biotech. 10 III cell extract wen: mixed with 200 III
buffer Z (60 mM sodium dihydrogen onhophosphate dihydrate, 40 mM sodium phosphate,
10 mM potassium chloride, 1 mM magnesium sulfate, SO mM p-mercaptoethanol) pH 7.0
after which 40.,al 4mglml ortho-nitrophenyl-p. D-gaiacto-pyranosidc was added and the
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solution immediately incubated at 31"C. After a yellow colour developed, the reaction was
stopped with 100 Jll I M sodium carbonate and the absorbence measured at 420 nm.
2.10 Lucifcruc asuys
20 IJI cell extract was mixed with 100 Jllluciferase reagent (Bior.ld) and the resulting
Iwninescence was immediately measured for 60 seconds in a luminometer (Monolight 2010.
Analytical Luminescence Laboratory).
2.11 Polymerase cbal. nactfoa (PCR)
DNA for PeR was extracted from cells using the QiAmp blood kit (Qiagen). PCR
was perfonned as recommended by the Strategene company, with minor modifications. SO
ng DNA (I IJI) and 10 pmal or each primer (lj.11 each), were mixed with 2 pI lOX PeR
buffer (Stratagene). 0.4 1.11 10 mM dcoxynucleoside triphosphates (Gibco BRL), 0.21l1 pfu
polymerase (Stratagene) and 14.4 III water. Reactions were carned out in the Perkin Elmer
Gene Amp 2400 PeR thennocycler. Reactions were carried. out under the following
conditions: 940(: for 3 minutes; 3S cycles of94°C for I minute, S5°C for 1 minute, 7ZOe for
1 minute; followed by 940C for 1 minute, SSOC for I minute and 72"C for S minutes.
2.12 ProteiD n1r.dioD
Proteins were extracted for western blotting as described by Yang et al., (1997). Cells
were washed twice with ice-cold PBS. 500 J.lllysis buffer (50 mM Tris pHS.O. 150 mM
sodium chloride, 0.02% sodium azide, 1% NP-40, 0.1 % 50S, 0.5% sodium deoxycholate,
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10 I-Lg ofl0 mglml pbenyl methyl sulfanyl fluoride (PMSF) and 5 I-LI aprotinin (2mgfml))
was added to each 10 em plate and the cells were harvested using a rubber policeman. Cells
were chilled on ice for 30 minutes to allow for their lysis. Lysates were then
microcentrifuged at 4"C for 10 minutes. after which the supernatants were transferred to
another tube and stored at -7O"C. Protein concentration was detennined using the BioRad DC
Lowry protein assay kit as instructed by the manufacturers.
2.t3.1 Westera blots
Western blots were perfonned according to the method orYang et aJ (1997). Proteins
were boiled in 2X SOS gel loading buffer (200 mM Tris pH 6.8, 4% 80S. 0.2%
bromophenol blue, 20"/0 glycerol) for 3 minutes and loaded onto a 80S-polyacrylamide gel.
The resolving portion afthe gel was prepared with 8-10'% acrylamide. 375 mM Tris pH 8.8,
0.1 % 80S, 0.1 % anunonium petSulphate, and 6 }1llctramethylethylenediamine (TEMED).
The stacking gel was composed of5% acrylamide, 125 mM Tris pH 6.8, 0.1%808, 0.1%
ammonium per5ulphatc and 5 J.ll TEMED. Gels were electrophoresed at I50 mV in SOS·
PAGE running buffer ( 25 mM Tris., 250 mM glycine) using a Protean n mirugel apparatus
(BioRad).
Following electrophoresis, gels, Hybond nitrocellulose membranes (Amersham) and
extra thick. filter paper (BioRad) were equilibrated in several changes of Towbin transfer
buffer (25 mM Tris, 192 mM glycine and 20010 methanol) for 30 minutes.
Proteins were transferred to nitrocellulose membranes using the Trans-Blot SO
transfer cell (BioRad). Soaked filter paper was put onto the stainless steel cathode and rolled
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with a pipette to remove air bubbles. Next, the membrane was placed on the filter. carefully
avoiding trapping any bubbles. The gel was then placed onl0 the membrane followed by the
second piece offilter paper, which is also rolled with a pipette. The platinum anode was put
in place on top of the stack and the proteins were allowed to transfer for 45 minutes at 20
vailS.
Blots werc: blocked for I hour with gentle shaking in TBS·T( 20mM Tris., 137 mM
sodium chloride pH 7.6 with 0.1 % Tween.20) and 5% skim milk powder. Primary antibody
was diluted with TBS-T containing 5% skim milk powder. Membranes were incubated with
the antibody overnight at 4OC. Next, memhl1ll1cs were rinsed briefly in TBS-T and then
washed in TBS·T once for IS minutes and twice for 5 minutes. Membranes were incubated
with the secondary antibody, which was also diluted in TBS-T and S% skim milk powder,
for I hour at room ternpen.ture. Membranes were washed in the same manner as described
for lite primary antibody. Protein detection was performed using the EeL system
(Amersham) and subsequently exposed to EeL film as instructed by the manufacturers. After
exposure membranes could be reprobed. ir desired.
2.13.2 ReproblDlofWaten membraDa
This protocol is an adaptation or the technique first described by Krajewski el at.,
(19%). The membrane was incubated in 5 ml TBS containing 50 j.11 diaminobenzedine
(DAB) and 2 III 30"/0 hydrogen peroxide with gentle agitation ror 30 minutes. The reaction
orthe proteins with the oxidized chromogenic substrate DAB, renders the protein-antibody
complexes unreactive during future reprobings. Blots were rinsed with tap water to stop the
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reaction and washed for two 1S minute periods with TBS at which time the blot could be
blocked and reprobed, as described above..
2.14 Far Weskra blots
This method ofdetecting protein-protein interxtion was taken from lnostroza d oJ.,
(1992), but with maay modifications. IS ",g of proteins were resolved on a loe/t
polyacryantide gel and fixed on a nitrocellulose membrane, as described previously. The
membranes were blocked with buffer A containing 20mM N-[2.HydroxycthyIJpiperazjnc-.N·
[2ethanesulfonic acid] (HEPES) pH 7.9, 50 mM sodium chloride, ImM EDTA and 10 m..'o1
I).mercaptoethanol and 5% skim milk powder at room temperature for 2 hours with genlle
shaking. Membranes were next incubated with 50 III P'SJ~radiolabclled i" vitro translated
VDR in2mI buffer B (20 mM TrispH 7.5, 140mM sodiumchJoride, 2 mM EOTA, 0.15%
NP-40. 2 mM dithiothreitol. 0.05% bovine serum albumin and S% glycerol) overnight at
4"C. Next. the membranes were washed 3 times for IS minutcs with TENNS buffer (10 mM
Tris pH 7.4, 2.5 mM EDTA. 140 mM sodium chloride, 1% NP-40 and 2.5% sucrose).
Membranes Wet"e subsequently subjected to autorMiognphy.
2.15 PrqtantkNl of wllok cdI. txtrac:ts for Electropbomic Mobility SlIlft Assays
(EMSAs)
Preparation of whole cell extracts was perfonned as described by Tasset el at.,
(1990), with some minor alterations. Cultured cells were grown to 80"'/0 confluence in 10 cm
plates, washed twice with PBS and harvested with SOO ...1high salt extraction buffer (0.4 M
38
potassium chloride, 20 roM Tris pH 8.0, 2 m.M dithiothreitol. 20-;' glycerol. 50 )lg PMSF
and 5 )lg Aprotinin). The cells were lysed with three freeze·thaw cycles in liquid nitrogen
and ice, respectively. The bomogcnatc was microcenb'ifupd at 4°C for IS minutes at 12,000
rpm and stored at ·7(]"C.
The scqucnceofthc sense: strand oftbe 27-mcrdoublc stnndcd oligonucleotides used
for protein.DNA interaction assays is shown below. The VORE contained in each stJand is
underlined. The oligonucleotide containing a consensus sequence VDRE (Santa Cruz) is a
DRJ type YORE. It consists ofadirect repeat oCtile sequence AGGTCA separated by three
nonspecific bases. This element is Icnown to be bound by a VDR-retinoid X receptor (RXR)
heterodimer. A mutated consensus was also used having two ofthe GT bases changed 10 AA
(shown below in italics). The second VORE is found in the p21 wo1l promoter region (Liu ~
01.• 1996). It is a DOD.consensus VORE. which has been found 10 be bound by both a VDR·
RXR heterodimer and a VDR homodimer.
AA AA
Consensus VORE 5' AGCTTCAQQICAAGG.M&KAGAGAGC 3'
p21-nVORE S' TGT~ATT~TGTCCAAT 3'
2.17 Ead I.bdl_. probes rorEMSA
10 picomolcs of sense oligonucleotide was incubated in a 500 )II PeR tube with 2
pi of 5X forward reaction buffer (Gibeo BRL), 10 units T4 polynucleotide kinase (Gibco
3.
BRL), and.5 ~I y-FP}ATP(Amenham) and water-to a final volwneoflO pI. The reactiOD
was carried out in a PCR thcnnocycler at 3teC for 45 minutes and stopped by heating at
7O"C CodD minutes. Then. 10 pmol DC antisense oligoouclcotide, 7.5 pi water and I pl20x
oligonucleotide binding buffer- (200 mM Tris pH 7.8, 40 mM m.agnesjum chloride, I M
sodium chloride and 20 mM EDTA) lft added to the same tube and incubated at 650C for
.5 minutes and ZS"C for 45 minutes to allow the oligonucleotides to anneal. The double
stranded oligonucleotides were purified using the nucleotide removal kit from Qiagen.
2.18 EMSAs
EMSAs were performed according to the instructions set forth by Pharmacia Biotech
in their EMSA tcchnical manual. 10 or 15 pg of protein from whole cell extract was
incubated with 1 X to-1 M I.2S-viwnm D3 in EMSA binding butrcr(IO m.f\.1 Tris pH 7.5,
1000/eglyccrol.80mM sodiwnchloride., 1 m..'f EDTA, oS mM dithiothreitol. 0.05% NP-40and
1.25 118 ofthe non-specific competitor poly dI-dC) for 10 minutes to activate the VDR. Next,
50.000 cpm of[llp} eod·labck:d DNA probe was added for a final volume or20 pi and the
reactions were allowed to procoed for 30 minutes al room tcmpcrantre. The reaction was
tenninated with 2 loll of lOX gel loading buffer (2S0 mM Tris pH 7.S, 0.2% bromophenol
blue. 0.2"'~ xylene cyanol and 44)-/. glycerol) and I~ed onto a 5% polyacrylamide gel. The
gel was made with a 6naI c:oncentralion orO.5x TBE(45 mM Tris pH 8.0, 45 mM boric acid
and 1 mM EDTA. The gel was NIl in the same 0.5 X TBE low ionic strength buffer at
ISv/cm. After electrophoresis, the gel was dried and exposed to x-ray fi(m (Kodak) for
aUloradiography.
2.19 GlatatlliOlle Sotraaskrase f... protria p.rilklltilta
Glutathione S-transferase (GS1) fusion proteins were purified according to the
manufacturer's (pbaramacia Biotech) instructions. Briefly, the BUI strain of E. coli
containing either an empty pGEX-4T-3 plasmid (phannacia Biotech) or with an inserted
gene were JI"OWD at 30-<: until the optical density at 600 nm reached 0.7. At this time:
isopropyl-jl.D-thiogaiactoside was added to a final concentration of0.1 mM and the culture
allowed to incubate for a further 5 hours. The bacteria were centrifuged. resuspended in PBS
and sonicated for eight 15 second bursts on ice. Triton X-IOO was added to a final
concentration of 1% and the Iysates mixed gently for 30 minutes. Lysates were centrifuged
at 12,000 X g and the supernatants collected. 400 ~I of glutathione Sepharose beads
(phannacia Biotech) were then added to the supernatant containing the desired proteins and
the mixture was incubated at room temperature for 30 minutes with gentle agitation. After
this, Wlbound proteins were removed with three PBS washings. GST proteins were eluted
wilh 10mM reduced g1utathione(Sigma) in SOmM Tris pH 8.0. Protein concentrations were
determined by SOS-PAGE comparison of I ",I of protein with bovine serum albumin
standanJs. Protein bands were observed by subsequent Coornassie blue staining.
2.20 GST protda biadla. assays
GST protein interactions were perfonned as originally described elsewhere (Hanada
et al., 1995). 10 "'8 ofGSTptOtein was incubated with II~I ofGlutathione-Sepharose beads
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for oue hour in HKM buffer (10 mM Hepes pH 7.2, 140 mM sodium <:hJoride. 5 mM
magnesium chJoride, I mM EDTA and 0.1 S% Nonidet P-40) to anac:h the proteins 10 the
beads. Next. S ...1of[l'S}-methionine ill vitro translated VDR prepared using the TNT T7
Quick coupled tr.mseriptiODftranslation SystCID (Promega) was incubated with the GST
proteins for 2.5 hours at 4"C. The mixture was washed six times with HKM buffer, after
which the beads were boiled in 20 J.l1 2X 80S gel loading buffer and 20 J.l1 was subjected to
80S-PAGE. After nmning. the gel was dried and exposed 10 X-illY film.
2.21 ADaonee iadepndnt (soft acar) cro~ asuys
Soft agar assays were performed acccxding to the method of Yang et oJ., (1996). The
underlay gel was prcpan:d by mixing 1.~l.autocJavcdagarosewith an equal volume of2X
DMEM and adding 12S mIlO eacb 6 em plate:. The overlay gel was prepared with 0.7%
autoclavcd agarose (cooled 10 4O"C) mixed with an equal volume of2X DMEM (coRlaining
1()3 cells per 1.25 m1 overlay) supplemented with 10"/0 FaS and 1.25 ml was added 10 each
plate. Colonies containing SOor more cells were counted after IS days.
.2
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Results
3.1 Bac-1laterKU wtdt "e~ D nuptor
Previous studies have shown the BAG· I can interact with a variety of steroid
hormone receptors (Zeiner et aI., 1995; Froesch et 01., 1998; Liu et al., 1998; Kullmann et
al., 1998). We thc:rd'o~decjdcd to determine ifBAGpSO could inlenet \\oith the vitamin D
receptor.
3.1.1 Far Waten blot
Fig.3.la shows the result ofa far Western blot in wbich GST and GST-BAGpSO
fusion proteins wcreprobcd with rSS]-mcthionine labeled in vitro translated VDR (Fig 3.1 b).
It was observed thai the VDR specifically interacted with GST·BAGpSO, but not the GST
protein.
3.1.2 GST p.u Dowa Assays
The structure of BAG-I reveals several domains which have potential to be involved.
in protein-prolein intenJClions. There are N-terminal and C-terminal a:·helical domains,
which are commonly the site ofprocein bc:tcrodimerization (Villanueva 1994; Marshall et 01.,
1993; Oleinikov 1993; Xing el al., 1994). In addition. the centrally located ubiquitin.Like
domain is a likely candidate for a dimerization domain, since ubiquitin is involved in
interactions with many proteins (CicchanovCf et at., 1991; Hershko and Ciechanover 1998).
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Fig. 3.1. Bludillg orVDR ud BAGpSO .sial Far westen blottiJla
Far Western blot showing specific binding aCthe VDR 10 BAGpSO. 10 Jig GST
(lane 1) or GST·BAG-I (lane 2) protein was separated on 10% polyacrylamide gel and
transferred to nitrocellulose membrane. The membrane was subsequently probed with in
virro translated VDR.
Fig. 3.th I" vitrtl tr..st-ted proteill prodacts
5 III p'S]-methioninc labeled in vitro translated VDR(lanc I) or hsp70 (lane2) as
a positive control. were separated on a la-;. polyacrylamide gel.
Fig. 3.1>
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Fig. 3.2 VDR specifically bluds .lIe p50 isoform of BAG-I.
The N terminal ofBAGpSO is responsible for its interaction with the VDR. Lane 1
contains 5 ~I [l'SJ·methionine labeled in vitro translated VDR. IOpg ofGST or GST-
BAG-I fusion proteins were immobilized on glutalhione-sepharose beads and incubated
with 5 III VDR (lanes 2-S). BAGpSO bound to the VOR (lane 3), but not the shorter p46
(lane 4) lacking 71 amino acids from the N tenninus or the p33 isofonn (lane 3) lacking
145 N tenninal amino acids.
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To analyze the BAG·1 isofonn and suuctural domain necessary for interaction with the
vitamin D receptor, full length BAGpSO, the p46 and p33 kDa isoforms were expressed in
GST·fusioD vectors and incubated with in vitro translated [JsS]-methionine labeled VDR
(Fig. 3.1 b). It was found that BAGp50 could strongly bind to the VDR. but did not inlenet
with non-specifically [J3S] labeled proteins appearing in the input lane (Fig 3.2), but. Neither
BAGp46 nor p33 however, could bind the VDR, indicating that lbc unique N-tenninal aCthe
pSO isofonn is the site of their interaction. It bas been previously shown that BAG-I's
binding to the hsp70 is not dependent upon the amino terminus (Takayama et al., 1997),
demonstrating that BAG-I '5 interaction with the VDR is independent ofheat shock proteins.
3.2.1 SI_ble traasfectioD of BAGpSO ia VII7 eells
To examine the effect of the BAGpSO-VDR inleraction in \/ivo, US7 glioblastoma
cells were stably transfected with the plasmid per3.l containing BAGpSO in the &:oRI
cutting site or an empty vector as a control (Fig. 3.3 a,b,c). US7 cells were chosen because
they express very low levels of endogenous BAG-I mRNA or protein (Fig. 3.3 a,b). This
result demonstrates thai BAG-l expression, while ubiquitous, can differ greatly in the
amounl of protein expressed and suggests that it may cell specificity. BAGpSO-stably
transfected cells will fonhwith be described as U87BAG-1 and per3.1 stably transfected U87
cells described as U8'·3.1.
3.2.2 Morpbo)ogy of t"'I:lSr~ledulls
The overcxprcssion of oncogenes in cells can often lead to morphological changes
48
Fig. 3.3. NortJlera blot of BAG-I mRNA ia ltably tnD.feet UI' etlb
20 J-1g mRNA from wild type U87 (lane I), US7·).1 (Jane2) orU87BAG·1 (lane3)
was separated on a 1% agarosc gel and immobilized on a nylon membrane. Membrane
was probed with [J:PHabeled BAG·I eDNA.
Fig. 3.Jb WUlcr. blot ofBAGp50 proteiD I.stably lrn.fect UI7 celh
10 Jlg total protein from US7 (Iancl)or U87-BAG-I was separated on 10%
polyacrylamide gel and transferred to nitrocellulose membrane. The membranes were
probed with I: 100 dilution arthe anti·human BAG-l monoclonal antibody CC9E8 and
I: 1500 dilution ofthc antHl-aclin monoclonal antibody.
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Fig. 3.3c peR product from U8' ails icably rra.sfected witb tile empty v"lor
per3.•
PCR3.1 specific primers were used to amplify SO ng ofpcr3.1 plasmid DNA (lane
3)or 50 ng total DNA from U87 wildtype (Jane2) orpcr3.1 stablytransfecled U87 cells
(lane 4). peR products were separated on a 2% agarosc gel along with a 100 bp DNA
ladder (lane I). Only lanes 3 and 4 show the 180 bp amplification product.
300bp -
200bp -
lOObp -
1 2 3 4
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FiX_ 3.4 MorpllololY of un wUdtype. U87-.J.l aad V87BAG-l cdII
Cells were grown on 6-wcll slides, stained with Eosin and Hac:matoxylin and
photographed at tOOX magnification. U87BAG-l cells are approximately 3X larger than
U87-3.1 cells. In addition, U87BAG-1 cells have a broader, more flattened morphology
when not in contact with other cells.
US?
• I
US?-3.1
US?BAG-l
,
'4
(Kato and Maeda 1997; Schuebeletal.. 1998; Sugiyamactal.,l998). Because BAG-I is
thought to be a potential oncogene, the morphology oCtile stably transfectcd BAG-I cells
was studied using Eosin and Haenwoxylin stained cells. Clearly, there are dramatic changes
in the BAGp50 overexpressing cells (Fig. 3.4). Many ofthe U87BAG·I cells arc three times
larger than those transfected with an empty vcctor (U8?-3.1). In addition, before the
U87BAG·! cells come in contact with other cells, many cells lose their angular profile and
become more rounded and flattened. The cells gencnilly return to a more normal morphology
once cell-eell contact occurs. The cytoplasmic 10 nuclear ratio appears to have remained the
same. These cells are similar 10 a type ofbrain twnor re£em:d to as giant glioblastoma cells
(McKeever 1998; Katoh et af., 1995).
3.3 EMSAs
The diverse cellular effects of the vitamin 0 honnone are carried oul through its
activation of the VDR. Once activated by 1.2S-vitamin 03 ( the metabolically active Conn
of vitamin D). the rec:eptorcan bind to its DNA response element as either a homodimeror
heterodimer with various other honnone receptors including the RAR (Nishikawa et aI.,
1994b) or RXR (Liu el aI., 1996a). The VDR can then help regulate transcription ofthe gene
in which ilS response element is located. It should also be noted that the VDR has the abilit)'
to bind to its response element as a homodimer in the absence of 1,25-vitamin 03 (Cheskis
and Freedman 1994). To determine if the binding of BAG-l 10 the VDR had any affect on
the ability of the VDR to bind to its response element, whole cell extracts were collected
from U87BAG-I and U87-3.1 cells and EMSAs were perfonned using an oligonucleotide
55
Fig. 3.5. EMSA ro..~..... aIId lDataat VDRE
BAGpSO intttftres with binding oCthe VDR to consensus VDRE. EMSA
reactions performed Y'ith a consensus DR·) type YORE. Lane 1 was loaded with free
probe. Lanes 2,3 an<!. , contain 15~g U87-3.1 whole cell extract. Lane 3 also had 300X
excess cold oligo. 'Ote reaction in lane 5 was perfonncd with a mutated YORE oligo.
Lane 4 contained 15 yi!; U87BAG·1 whole cell extract. The lop arrow points toward the
VDRIRXR complex Pld the bottom arrow indicates the position ofunbound probe.
VDRJRXR -+
I 2 3 4 5
56
57
Fig. J.5b EMSA for aH-<ODse.'.' VORE from p21""" promoter repoa
EMSA reactions performed using a VDRE containing oligo &om the p21 oral1
promoter. Lane I was loaded with free probe. Lane 2 and 3 contain 10 ~g U87-3.1 whole
cell extract Lane 3 also had 300X excess cold oligo. Lane 4 contained 10 I1g
U87BAGpSO whole ceU extract. The open triangle points toward. putative VDRIRXR
complex and the closed triangle a VDR homodimer.
:2 3 4
59
containing a consensus VORE. The complex bound to this consensus YORE was likely a
VDRIRXR beterodimer (Fig. 3.5a lane 2), which was previously sbovm to bind a consensus
VORE (Nishikawa et al., 1994a; lin et aJ., 1996). EMSAs perfonned with extracts from
U87BAG-l however, showed a greatly reduced amountofVDRIRXR. complex binding to
the VDRE (lane 4). To determine ifBAG-l could also inhibit the VDR from binding to DNA
as homodimer. a YORE from the p21-rl promoter was employed. It was previously
demonstrated that the VDR could bind this YORE as a homo or bcterodimer (Liu et aJ.,
1996a). It was found that two complexes could bind this response element (Fig. 3.Sh),
corresponding to the complexes previously described (Liu el al., 1996). Specific competition
for the oligo was shown by adding 300X excess unlabeled oligonucleotide (lane 3). Extracts
from U87BAG-l however, showed significantly Jess VDR DNA binding as either a
homodimer or heterodimcr (Fig. 3.Sh, lane 4). This suggests liIat BAGpSO can bind to the
VDR in cell extract and that this binding abrogates the ability afthe VDR to bind to its
response element.
3.4 CAT assays ia U87-J.I ud U87BAG·1 eells
The previous experiments suggest that BAGp50 is capable of down·regulating 1,25-vitamin
OJ-mediated transcription by blocking the VOR from binding to its response elements. To
investigate this hyPothesis, US7-).1 and U87BAG-l cells were transfected with the CAT
reponer plasmid VDREtkCAT. containing multiple copies of the VORE belonging to the
osteocalcin gene. Twenty four hours after transfection., l<t' M 1,25·vitamin 03 was added
to the cells. CAT activity nonnalized with the luciferase reporter plasmid PGL) or by
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Fig. 3.6 Comp.rilOD of vttuaia D).gduced CAT aettvatioD lD U81~3.1 lUld
U87BAG-1
cells.
Vitamin D3·mcdiated transactivation is down-regulated by BAGpSO. 2 f.lg of the
plasmid VDREtkCAT was transfccted into US7-3.1 and U87BAG-J cells in 6 well plates.
Total DNA was normalized to S",g. Vitamin 03 was seen to activate the VDRE
containing CAT construct VOREtkCAT 5.9 fold in US73.l cells stably transfccted with
empty vector. In U87BAG-1 cells that overexpress lile pSO isofonn of BAG-I however,
this activation was reduced to 2 fold.
U87BAQ·1
01- _
1,2S(OHhD3
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equalizing total amount of protein used in each CAT assay (Kullman et aI., 1998). In the
presence ofhormone, CAT activity was increased OVCI" 5 fold in US7-3.1 cells (Fig.3.6). In
cells containing BAG-l however, activation by 1,25-vitamin OJ was strongly repressed and
only an approximate 2-fold induction was observed. This suggests that BAGpSO is a negative
regulator of VDR-mediated transcription in vivo. These experiments were also repeated in
C33A-3.1 and C33A-BAG-l cervical carcinoma cells (these cells were provided brYang
et al., unpublished data), but 1,25-vitamin D3 had no effect on CAT activity in this system.
These results point towards BAGpSO being a novel repressorofVOR activity.
3.5 Proliferation Assays
l,25-vitaminD3 has been reponed to have anti·proliferativceffects on nu:merousccll
lines, including MCF·7 breast canctt cells (Simpson el al., 1987). lymphocytes (Rigby el ai.,
1985) and others. We next decided 10 investigate ifvitamin 0 had any affect on the growth
orUS? cells, and ifso. whether the overc:xpression ofBAGpSO could inhibit this effect. 10-'
M 1.25-vitamin D3 was added to US?·].l and U87BAG-1 cells plated at a densiry of H)'I
cells per well in 6 well plates. 1,2S-vitamin 03 was found to inhibit the growth ofU87-3.1
cells by over 30"/0 over a six day period (Fig. 3.7). Compared to U87-3.l cells, U87BAG-1
cells grew at a much faster rate. The untreated BAG-I cells grew 79''.10 faster than their U87-
3.1 counterparts after a six day period. Interestingly, 1,2S-vitamin 03 had no effect on the
growth ofU87BAG-l cells over a 6 day period, demonstrating that BAGpSO rendered these
cells resistant to the growth inhibitory actions of I,2S-vitamin 03. This also lends supporting
evidence that BAG-l and the VDR can bind in vivo and that this binding abrogates the DNA
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Fig. 3.7GrowG 1ISU)'I ofUI7~3.1 ..d VI7BAG-t ill prance ..d absnceof
vlt.mi. D3.
BAGpSO increases proliferation 0(U87 cells and induces resistance Co vitamin
D3-mediated proliferation inhibition. Growth ofU87-3.1 cells under normal conditions is
taken to be lOO"Io.Vitamin 03 is shown to reduce the proliferation orU87-3.1 cells (0).
Overexpression ofBAGpSO in U87 cells is seen to enhaDce the rate or proliferation (e)
and confers vitamin 03 resistance upon the cells <.).
200
180
160
1i 140
E 120<
B 100
m
~ 80
~ 60
40
20
0
0
• U87BAG·l
• U81BAG·1 + 03
o U87-3.I+DJ
..... "'0
'". ·····0 "0
Day
..
65
binding potential ofVOR.
3.6 Westen bkJttlB. oCtile VDR
Studies have shown. that ccUularVDR levels increase in response to I.2S·vitamin 03
and that this increase is neeessary to observe the anti-proliferativeeffccts of l,2S-vitamin 03
(Wiese el a/., 1992; Santiso-Mere CI al., 1993; Solvsten et at., 1997). Protein levels are
thought to be increased through both an increase in transcription (Taolca ct al., 1993 and
Cornet et 01., 1998) and enhanced protein stabilization (Wiese ct al., 1992). VDR levels were
assayed in the BAG-! negative, US7 glioblastoma and e33A cervical cclilines after the
addition of l,2S-vitamin 03 for 6 and 24 hour periods. A moooclonaJ VDR antibody
(Affmity Bioreagents) at a 1:1000 dilution was used to detect VDR protein levels. The level
ofVOR was seen to rise in both cell lines after the addition of l.2S-vitamin 03 (Fig. 3.8a).
The faint upper band seen in US? cells after the addition of I ,25-vitamin 03 is probably due
10 VDR phosphorylation. as previously described (Iwata et aJ., 1996; Jurutka el aJ., 1993).
As mentioned above, increased VDR levels are thought to be necessary for the
cellulaT effects of I ,2S-vitamin 03 to occur. Therefore, it was believed that ifVDR levels
were unable to rise in U87 cells in response to l,2S-vitamin 03 stimulation, that the resulting
decrease in proliferation may not occur. Therefore, we hypothesized thai a possible
mechanism of action by BAG-l to inhibit the cellular actions of I,2S-vitamin 03 could
involve decreasing VDR levels via binding and inhibiting the nonnal function oftbe YOR.
To test this hypothesis. we again utilized Western blotting to detect VDR protein levels in
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Fig. 3.8a Westera blot ofVDR Ia un ad CJ3A cells.
10 ~g of protein from C33A and US7 cells was resolved on a 10"/0 polyacrylamide
gel and tnlnsferred to a nitrocellulose membrane. Blot was probed with 1:1000 dilution of
VDR monoclonal antibody. Lane I contains wild type protein. Lanes 2 and three contains
prolein from wild type cells after the addition of 10-' M vitamin 03 for 6 and 24 hours
respectively. The same blot was stripped and subsequently reprobed with 1:1500 X
dilution of I3-Actin.
Fig. 3.Sb Welten blot orVDR from U8,-3.• aad V87BAG-l c:ells.
10 ~g protein from US7-3.l (lanes 1 and 2) orU87BAG-1 (lanes 3 and 4) was
resolved on 1()Cl/o polyacrylamide gel and transferred to nitrocellulose membrane.
Membranes were probed with 1:1000 X dilution ofVOR monoclonal antibody. Lanes 2
and 4 contain protein from cells grown in the presence of to-7M vitamin 03 for 24 hours.
Fig.3.8a
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Fig. 3.9 Growth of Un-l.! u' UI7BAG-t .. soft .....
1 x 10' U87-J.t orU87BAG-1 cells were seeded in soft agar and grown for IS
days. U87BAG-I cells formed 84% :*:13% more colonies. The colonies formed from
U87BAG-1 cells were also significantly larger in diameter. Photographs were lakcn at a
magnification of2SX.
U87-3.!
U87BAG-!
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U87·).l aDd U87BAG-1 cells after the addition of 1,25·vitamin 03. It was found thac the
presence of BAG-l significandy reduced the lDcreasc: of VDR in response to ligmd
stimulation (Fig- J.Sb).
3.7 Soft Apr Asuys
h has previously been reported that proliferation-promotiDg factors such &5 the
epidermal growth factor receptor aDd interieuk:in 6 can enbancc the colony formation of
transformed cells in soft agar (Okamoto et at., 1998).To further investigate the pro-
prolifc:r.uive abilityoCBAG·l. we subjected US7-3.1 and U87Bag-l cells to soft agar assays.
Increased rates of cellular proliferation and tumorigenicity are known to be related (Chen ct
al., 1998; Popik and Inglot 1987). Therefore. an increase in soft agar colony [annation by
BAG-} overexpressing cells would lend support to its oncogenicty. as well as confirming its
pro-prolifemive capability. In addition. we investigated whether the addition of 1,25·vitamin
03 to the cells in soft agar could inhibit their c1onallfOwth, since it has been reponed to do
so in other cell lines (Yoneda CIOI., 1984; Dok:oh et al.• 1984, Haussler et aJ., 1986).
U87Bag-l cells fonned 84%~13%morecolonieslhanU87·3.lccUs. ofSO cells ormore (fig.
3.9). after a period of IS days. Interestingly, the colonies formed by BAG· I overexprcssmg
cells were significanlly larger than lheir U87·3.l counlerparts (Fig. 3.9). I.2S-vitamin 03
had no effect on the growth of the cells. These results demonstrate again that BAGpSO can
increase the me ofcell proliferation and may confer an increased tumorigenic potential upon
cells.
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Fig. 3.10 Exprasioll or BAG-l maNA ill .onDal duge
Nylon membranes containing mRNA from a variety ofnonnal tissue were probed
with BAG-l eDNA. Membrane was subsequently stripped and reprobed with p-Actin
eDNA.
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3.8 Equasioa of BAG.I .. aormal dssae
The classical l.,2S-vitamin 03 WJcl: tissues are the bone, skin, kidney and intestine.
The VDR has also recently been found at highly variable levels in the prostate (lGviniva et
aI., 1998). To determine ifBAG-I expression corrcspondcd with VDR expression, mUltiple
tissue Northern blots (Clontceb) wercprobcd with BAG·l cDNA(Fig 3.10). BAG-l mRNA
expression showed tissue tropism, but no obvious pattern of expression could be discerned.
BAG-l was found at relatively high levels in bone marrow and the prostate but was virtually
absent in the small intestine. Previous studies have found BAG-l at high levels in the kidney
but very low levels in the skin (Takayamaet al., 1998). Our results indicate that high level
of BAG-I correlates with high VDR levels only in bone marrow tissue.
3.9 Effect o(SAGp50 on l,25--vltalmla D3-medlated iDdacdoa ofpZlWOfl
1.2S-vitamin 03 is known 10 be an inducerofp21Q!\ transeriptionand this is thought
to be one oCthe mechanisms through which 1.25-vitamin 03 call inhibit proliferation (Liu
el al.• 1996). Our resuils showed thai I ,2S-vitamin 03 can inhibit U87 cell growth. so we
decided to test if the honnone had any effect on p21-n transcription. This was actUevcd by
transfecting cells with luciferase reponerplasmids containing the p21-n promoter/enhancer.
Transfections were normalized with the CAT reponer plasmid PSV2CAT or by normalizing
the total amount of protein used in each luciferase assay as described by Kullman el QI.,
(1998). We found that 1,2S·vitamin 03 had no effect on the p21-n promoter in U87 cells,
but could induce p21-n transcription in C33A cells (Fig. 3.11). We next investigated if
BAGpSO could inhibit this induction. To accomplish this, C33A cells stably trasfectcd with
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Fig. 3.11 Effect of BAG-l OD vttamill D3-Uidaced .prep..tioa of pll...n
lraDSCI'"iptioD.
I I!g of the plasmid p21-4 containing the p21.....n promoter in a luciferase vector
was transfccted into C33A cells stably transfected with empty vector (C33A-3.1) or
BAGpSO (C33A-BAG-l). Transfections were nonnalized to total ofS III plasmid DNA.
10.7 M vitamin 03 was added to cells 24 houn post transfcction where applicable.
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Fig. 3.12 EMSA (or pl1""VDRE wttll utrac:t(rom e33A-J.t ..d CJ3A-BAG-I
cells.
10 ~g extract from el3A-3.l Oanes 2 and 3) and e3lA-BAG-1 (lane 4) was
incubated with 50,000 cpm radiolabcled p2l wafl VDRE. Lane 1 contains free probe and
lane 3 contains 300X excess cold oligo. Arrow indicates bound VDR complex.
134
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BAGpSO were utilized.. We rOUftd thai BAGpSO couJd inhibit the tnnscriptiooal iDcrease of
p21 wa1l promotCl'"by 1,25.vitamin 03 (Fig.3.II).
Next we investigalCld wbetbel-BAGpSOcould inhibit the binding oftbe VOR to the
p21...n VDREinC33Accllsas it did in U87 cells,lD1e:restinglr, it was found thal only one
complex from C33A cxtrx1 bound to this VDRE (Fig.3.12). Tbc preseDCe ofBAGpSO
inhibited its binding. Fw1her experiments showed that no bindiDg to the consensus YORE
could be observed (dala noc: shown). Tbe complc:x bound to tbepll-n VDRE in tbisceU line
is likely a VOR homodimer and DOt a VDRIRXR heteTOdimer, siDCe the VDRIRXR
heterodimer is necessary 10 activate the ostcoca.lcin YORE fowKl in the VDREtkCAT vector
(50n= el 01.,1991). The fact that I,2S-vitamin 03 has no effcct on this CAT constnK:t in
these cells (as mentioned above) and that DO binding to the consensus VDRE is observed in
e33A cells. suggests that the VDRIR.XR hcterodimer does not fann in e33A cells and that
the complex. bound to the p21-n promoter is a VCR homodimer. This also proposes thai
p21"~ transcription can be regulated by a VCR homodimcr in this cclliinc.
It has been shown that gluc:oc:orticoids can down-regulate cellular BAG-l levels
(Clevengeret 01.. 1991). In rum. BAG-l can inhibit the cellular actions ofglucocorticoids.
(Kullman etal.• 1998). Thus, it appears that BAG·I and g1ucocorticoids act in opposition to
one anomer in a negative feedback loop. To investigate whether BAG-I and I.2S-vitamin
03 can work in this fa.shion. the BAG· I promoler/enhancer contained in the luciferasc veclor
PGL2 (Yang etal., 1mb) was utilized. This COnstnlct was transfected inlo e33A and U87
cells with and without the addition of l.2S-vitamin 03. It was found that 1,2S·vitamin D3
had no effect on the level of BAG· I transcription in these cell lines (dala not shown). This
7.
assay also demonstnIes that l,2.S-vicamin 03 is not a norupecific sinlua.torofnnsaiption.
3.10 1E:trm:.rBAGp46Hdtep21-'p~
To iDvestipte whether BAGp46 could inhibit the effects of 1,25·vitamin 03, we
cotransfccted the p21 wt4'l promoter region with this isofonn of BAG-l aDd added 1.25-
vitamin 03. Interestingly, we found that BAGp46 could decrease p21-n transcription in
C3)A cells by 75% (Fig. 3.13). When 10-' I,2S·vitamin03 was added there was an increase
in p21"-:on promoter activity, which was repressed by the presence ofBAGp46. However, it
is also possible that the addition ofl,2S-vitamin 03 abrogated the traII5criptional repression
of p21 ....n by BAGp46 or that the two effects were additive.
Next, we decided to de1enni.ne if the BAGp46 could repress p21 wafl transcription in
another celliinc. It was found that BAGp46 could also inhibit p21-n transcription in U87
cells (Fig. 3.14). Transcriptional repression in these cells was slightly weaker than in elJA
cells.
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Fig. 3.13 Neg_dve rquladoa ofp21...n trusc:ripu. .. C33A cdIs.
5 Ilg ofthe plasmid p21-1uc containing the p21 waf1 promoter in a luciferase
reporter vector was transfccted into C33A cells grown in Scm plates with varying
amounts ofBAG-Ip46. Total plasmid DNA was normalized to IS Ilg. 10-7 M vitamin 03
was added 24 hours post transfection where applicable.
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Fig. 3.14 Neg_tin rep"dH of p21"1ft traasertptioa ia UB' aUs.
5 j.lg of the plasmid p21-luc containing the p21-" promoter in a luciferase
reporter vector was transfccted into cells grown in 5 em plates with varying amounts of
BAGp46. Total plasmid DNA was normalized to ISJ,l8.
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CHAPTER 4
DISCUSSION
4.1 BAG-I i.teraets wltb ~eVOR
Human BAG-I was originally isolated due to its ability to bind the OR (Zeiner and
Gehring 1995). Since that time, it has been found to bind, and also modulate the function
of the OR (KuUman et aJ., 1998), AR (Froesch etal., 1998) and RAR (fakayama et ai.,
1998).ln tbisstudy, it was found that BAGpSOcould bind the VDR.
Each of the previous reports described a different isoform of BAG· I binding to a
steroid hormone receptor. BAGp46 was found to bind the GR and BAGp33 was found 10
bind the RAR. It has not been investigated whether other isoforms can bind these receptors.
The AR was found 10 bind to BAGpSO but not to shaner BAG· I isofonns.
Here, Far Western blotting (Fig. 3.la) and GST·fusion protein pull-down assays (Fig.
3.2) were employed 10 demonstrate the VDR·binding potential ofBAGpSO. As with the AR...
the VOR bound specifically to the N-terminus of BAG-I as was dctennined in GST-fusion
protein assays. The C-tenninal of BAG-I is responsible for binding to hsp70 (Takayama et
ct, 1997). Therefore, it appears that BAG·I binds to the VDR, RAR and AR independenlly
ofhsp70. This is important, because Zeiner et Qt., (1997) found that BAG·J could interact
with a variety of proleins indirectly via hsp70. The N·tenninus ofBAGpSO has no readily
apparenl secondary structures that may be involved in protein.protein interactions. Site.
directed mutagenesis of BAG-I '5 N·terminus would be useful for detennining which amino
acids are necessa!)' for honnone receptor binding.
8S
Far Western and GST-fusion protein binding show that the VDR does not need to
bind I,2S-vitamin 03 to bind BAG-l in vi"o. It bas been found that several VDR
cou:tivaIOI'S. such as steroid receptorcoactivator I, interact with VDR in a l,2S·vitamin D3-
dependent manner (Gill et al., 1998). Further work using the yeast two hybrid binding
system and immunoprecipitation is necessary to detennine ifBAGpSO can bind the VDR
independently of I,2S-vitamin 03 in vivo.
BAG-l contains two potential amphipathic a-helical domains. These motifs have
been shown to be important for binding of other proteins 10 the TFIm and TFIID
components ofthe basal transcriptional machinery (Latchman 1990). In addition, the steroid
receptor coactivator GRlPt has been shown to interact with receptors through an
amphipatlric a-helical domain (Darimoot et aJ., 1998). This suggests that BAG-t may Conn
a novel link between nuclear receptors and the basal transcription machinery. It would be
interesting for future studies to explore lhe potential relationship ofBAG-t with TFlm and
TFIID. A N-terminus a.-helical domain is found in both the p50 and p46 isoforrns of BAG-I.
This motif was shown not to be necessary for in vitro binding to the VDR. but may be
important for proper binding or joining accessory proteins to the ¥DR complex in vivo. This
is possible, since the binding of nuclear honnone receplors 10 DNA and subsequent
transcriptional regulation involves a number of coactivators. corepressors and other proteins
involved in chromatin restructuring (Horwitz et al., 1996; Haussler et al., 1997). To identify
any VDR accessat)' proteins or other new proteins that interact with the N-tenninus of
BAGpSO, die yeast two-hybrid screening system could be utilized using a truncated BAG-I
containing only the N-terminus as bail protein fused to the Gal4 DNA binding domain.
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4.2 Stable trusfectio., of un CUoblutoma cells
To further study the interaetionofBAG-l andtbe VDR.stablctransfectionsofc::ells
with the BAGpSO protein (Fig. 3.3b and Fig. 3.4) wen: be made. Cells lacking BAG-I were
considered most suitable for constructing stable transfectants, because there would be no
background effects of endogenow BAG-I. In addition. it would be clear in subsequent
studies with these cells, that any cellUlar or molecular changes would be due solely 10 the
presence ofhigh levels aCthe BAGpSO. but not other isofomtS. U87 cells were considered
to be ideal because, of the two available BAG· I negative cell lines (U87 and e33A), US7
was the only one which responded to 1,2S-vitamin 03 with a reduced rate of proliferation.
Past studies also have shown different glioblastoma cell tines to be sensitive to l,lS-vitamin
03 (Margrassi el ai., 1995).
The most obvious change in U87BAG-l cells was their altered morphology (Fig.
3A). Many aCthe cells were larger. rounder and flatter than their U87-3.l counterparts. This
is similar to the morphological changes that were reponed when primary cells were
immortalized by oncogenic factors such as human papillomavirus type 16 (TsulSumi et 01.,
1992) and the K·ras protein (Sugiyamaetal., 1998). It is not yet undemood what intraeelluar
changes occur that lead cells to have this altered morphology. A change in stnJctural protein
expression seems possible. Undoubtedly however, there must be numerous changes in gene
expression 10 account for these features. Differential display would be a useful technique 10
help reveal genes having altered expression in U87BAG·l cells. The fact that BAG-I
tnlnsfecled cells exhibil a morphology similar 10 other cells overexprcssing oncogenic factors
also implies that BAG-I itself may be a proto-oncogene.
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Interestingly, a rare type ofgiant cell glioblastoma exists. The cells ftom these tumors
an: enonnous. measwi.ng up to 400 ~m in diameter (Kalab el aJ., 1995). Giant ceU
glioblastoma cells are often mulitimx:leated but an:: not formed from cell fusion (McKeever
1998). There have been few studies perfonned on these rare tumors. One study found that
12 of 16 tumors had mutated pS3 proteins (peraud et aJ., 1997) and others have found high
immunohistochemical staining ofprolifenltlon markers such as proliferating cell nuclear
antigen (McKeever 1998; Katah et af., 1995). Mutated pS3 alone however couldn't explain
the strange pbenotype exhibited by these cells. It would be worthwhile to examine these
tumors for BAG-l expression, since they show a morphology similar to BAG·l
overexpressing glioblastomas.
In addition to the morphological changes, BAGp50 was shown to increase the basal
proliferative rare of these cells (Fig. 3.7). BAG-I overcxpression was previously shown to
have some correlation with survival and proliferation in while blood cells. but BAG·}
overexpression alone did not directly increase the rale of proliferation of these cells
(Clevenger ef al.,1997). BAG· I was demonstrated 10 make an interleukin-3-dependent cell
line proliferale independently ofinterleukin-3. BAG-I protein levels were also shown to be
upregulated by interleukin·2 (Adachi el al., 1996) and Interferon-y. Both interleukin-2 and
interferon-y have been shown to increase cell proliferation (Mehrotra ef al.• 1995 and
Widschwendter el al.. 1995) in T lymphocytes. Hence. BAG·I may be involved in the
induction of proliferation by these. and maybe other. cytokines.
The involvement of BAG-l in cell growth was funher supported by the fact that
BAG-l transfected cells could fonn more colonies in soft agar than non·transfected cells.
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A potential future study would involve stably transfc:ct OOfHUIDOrigeniC baby rat kidney cells
with the various BAG-l isoforms and investigate whether BAG·I could confer
immortilization and the ability to grow in soft agar or form tumors in nude mice upon these
cells. Since BAG-} can inhibit apoptosis in several cell lines, it is reasonable that U87BAG-l
too, could be resistant to apoptosis. IfU87BAG-l cells do have heightened protection from
apoptosis, il would be interesting to study what agents could overcome this resistance. These
may include apoptosis-inducing drugs such as cisplatin. etoposide, etc.
Proliferation is a complex biological process and involves a large number of
interrelated factors, such as cell stimulation by hormones and cytOJcines and their related
signal transduction pathways. Also, cell cycle-related proteins, such as eyelins and their
inhibitors, play an essential role in proliferation. Taking the number of factors involved in
proliferation into account, it is difficult to speculate on the exact role that BAG-) is playing
in proliferation. However, regulation of proliferation through modulation of honnone
receptor function may certainly be one mode of action.
4.3 BAGp50 can inbiblt t.lae biadla. or DNA by tbe VDR
Transcriptional transactivation by steroid receptors is influenced by accessory factors
through several mechanisms. These accessory factors can fonn a direct link between the
receptor and the basal transcriptional machinery, remodel chromatin structure, or interfere
with the ability ofthe receptor to bind DNA. After observing the interaction between BAGSO
and the VDR, the next question that needed to be addressed was whether the binding ofthe
VDR by BAGpSO had an effect on the ability of the VDR to bind its DNA responsive
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element.
It was [ound that the VDR contained in cell extracts from U87-3.1 could bind to a
consensus YORE and a YORE from the p21""" promoter with high affinity (Fig. 3.5a and
b). The presence ofBAGpSO in the U87BAG-l cell extracts greatly diminished the binding
of the VDR to YORE containing oligonucleotides. BAGpSO could apparently inhibit the
binding ofVOR as eithera homodimer or heterodimer. BAGpSO may abrogate DNA binding
by the VDR via several mechanisms. BAG·} may bind to the DNA binding domain aftbe
VOR, thus blocking the functionality of this domain. The binding of BAG· I to the VDR
could change the confonnation of the VDR which could result in an inability 10 bind DNA
or form dim~. Finally, BAGpSO may simply sequester the receptor to some region in the
nucleus. Funher work could explore the exact mechanism oElhis inhibition.
4.4 lahlbltioa of 1.1~vil.miaD3-mediated traauctivatioD by BAG-I
A corepressor is a protein that can repress the activity of a nuclear receptor through
one of several mechanisms. These mechanisms include: I) binding of the corepressor to a
response element that overlaps the honnone response elemenl, thus competing out the
honnone receptor 2) the repressor competes with the receptor for binding to the basal
transcriptional machinery then:by interferes with the receptor activity 3) The repressor binds
the receplor and inhibits its ability to bind DNA. There have been several corepressors
discovered thai antagonize sleroid bonnone receptors (Horwitz el 01., 1996). Up to the
present, the calcium binding protein calreticulin is the only known corepressor of the VDR
that binds the VDR and blocks its DNA binding ability (Wheeler el 01., 1995).
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Based on the aforementioned results, we dc:cidcd to investigate wbetbc:r BAGpSO had
any corepressor' like influence on l.2S·vitamin D3-mediated transcription iff vi\.'O. A CAT
rcponc:r plasDtid containing multiple VDREs in taDdcm, 1nIDsicotly transfectcd imo U87-3.1
cells was stimulated over S-fold by the addition of l(tT M l.2S-viwnin 03. However, the
same c:onmuct transfeclcd into U87BAG-1 cells showed less than • 2-fold induction when
stimulated by the same hormone (Fig. 3.6). lbis suggests that BAGpSO can regulate 1.25-
"itamin D3-mediated transadivation in \/Wo. In addition. it also suggests that the intenction
between BAGpSO and the VDR can also occur in Vivo.
Similarly, it was found that BAGpSO could block 1.25-vitamin D3-induced
transaclivation of the p21-n promoter in e33A cells (Fig. 3.11) demonstnlting thai
inhibition ofthe VDR by BAGpSO is not promoter or cell specific. Transcription of p21.-ar1
could not be stimulated by I,.2S·vitamin 03 in U87 cells suggesting that other transcriptional
factors were blocking, or necessary for, 1,.2S-vitamin DJ·mediated action on this promoter
and these factors were not present in C33A cells. This rault also suggests thaI 1,25-vitamin
03 may utilize a p21...n independent pathway in U87 cells to inhibit proliferalion or
ahematively, may regulat.e p21....n expression on a post-tnnscriptional level as previously
reponed to occur in a proswc cancer cell line (Zhuang and Burnstein, 1998). Ofcourse, the
actual lnUlscription of genes from chromosomal DNA is very different than that from
plasmid DNA in that chromatin stnJcture and DNA methylation play an important role.
In agreement with the binding and tJansactivation studies were results showing that
BAGpSO could confer resistance to 1,2S-vilamin D3-mediated reduction of proIi feral ion
(Fig. 3.7). This also proposes that BAG-! can interact with, and regulate the function of the
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VDR in vivo. Further work is needed Co show that the BAGpSo-VOR interaction bas
significance in other cell lines. The fact that BAGpSO is primarily localized in the nucleus
indicates that it may function as a regulator of steroid receptor function under normal
physiological circumstances. 1bc overexpression ofBAG-l may playa role in the resistance
of cells to new l,25-vitamin 03 analog-based tbcnpies that are being developed.
It seems possible that the physiological role ofBAG-I is to regulate the function of
steroid honnonc receptors. BAGpSO was previously reponed to bind, and enhance AR-
mediated proliferation. BAGp46 and p33 were reported to bind and inhibit the functions of
the GR and RAR respectively. Under normal circumstances, BAG-I could be regulated at
the level oftranseription or translation to help regulate the cellular response to hormones. For
example, ifa cell is at a stage in which it needs to resist the actions of 1,25-vitamin 03, the
ceHular levels ofBAGpSO could be upregulatcd. Conversely. if a cell needs 10 enhance the
effect of I,2S-vitamin 03, such as increasing calcium absorption in the intestine or slowing
me rate of cell growth, BAG-I could be down-regulated. Recently, it was discovered that
BAG-I protein levels could be lowered by the addilion of glucoconicoids to a lymphocyte
cell line (Clevenger et oJ., 1997). Considering the inhibilory effects of BAG·I on GR·
mediated transcription (Kullman et aJ., 1998), this suggests that BAG-I may be involved in
a negalive feedback loop within !he glucoconicoid pa!hway. Similarly, it !las been found that
the promoter region of BAG-I contains a consensus VORE (Yang et aJ., 1999b). (1 is
unknown al this time what, ifany, role this response element plays in the regulalion of the
BAG-I protein. Further work might find that BAG-I. and the VDR., are involved in a
negative feedback loop. (f this is true, and BAG-I is overexpressed as the resull of some
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cellular disruption, it could have a snowball effect in increasing its own protein levels. By
repressing the action or its own inhibitors (steroid honnone receptors), BAG·\ would be
actively increasing its own transcription. This may be a factor in BAG· I 's potential role as
an oncogene. In addition, BAG-I was found to be localized in the nucleus and cytoplasm at
different ratios al different times in the same cell line (Takayama el aJ.. 1998). This may
potentially be due to the action ofhonnones. Future work could study the effect ofhonnones
on BAG-I expression in various types ofcells.
As previously discussed. BAG-J has been found at higher-levels in breast tumors than
the surrounding wild type tissue (Zapata et al., 1998). Steroid honnene receptor status is
often used as a prognostic marker for breast canccr{Ravaioli et ai., 1998). IfBAG-J were
up-regulated in cells, this could lead 10 malfunction of hormone rec:eptors and a loss of
proliferation control. This could explain why the status of harmone receptors in breast
carcinomas is not always a reliable predictor ofoftumor status (R.a.vaioli et a/.. 1998; Allred
el 01.• t998). Even if hormone receptors are present. their function may be altered by
increased BAG·I levels. Conversely, in the case of the AR, increased BAG-l levels may
increase the receptor activity, resulting in resistance to androgen antagonists that are used for
prostate cancer treatment. Further work is necessary to study lite correlation ofSAG-I levels
with hormoneJhormone antagonist resistance.
4.5 BAGp50 caD lower VDR proteiD levels
One possible explanation fot the inhibition of 1.2S·vitamin D3 action by BAGp50
is the fact that increasing BAG· I levels results in the inability of 1,25-vitamin D3 10 up-
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regulate its own receptor (Fig. 3.Sb). As previously mentioned, 1.25-vitamin 03 bas been
reported to increase its receptor's level by increasing VDR stabilization and through
heightened transcription (Wiese 1992 ; Taoka 1993). Some studies suggest that the binding
of 1,25-vitamin 03 to its receptor induces a conformational change. resulting in increased
stabilization of the protem (van den Bernd et al., 1996). It is also possible thatlhe VDR
upregulates the transcription of proteins that activate VDR tnns<:ription or increase VDR
stabilization. However, the precise mechanism of vitamin D-mediated up·regulation of its
own receptor is unknown at this time since the VDR promoter/enhancer does not contain a
VDRE (Jehan and DeLuca 1997; Crofts et al., 1998). This study suggests that BAGpSO
could block 1,,25·vitamin D3-medialed up-regulation of its own receptor through abrogation
ofVOR DNA binding ability. But the exact mechanlsm ofthis inhibition is unknown. Future
work could examine VDR RNA levels in response 10 1,25'v1lamin 03 in US'-3.l cells. If
unchanged, the increase in VDR would be due to increased protein stabilization. Ifthis were
the case. the binding ofBAG· I to the VDR may result in an inability ofthe VOR to bind its
ligand. thereby negating iI's stabilizing effect. Future work could delermine Ihe domain of
the VDR involved in BAG-I bindi....g. IfBAG-) bound lathe DNA or ligand binding domain
of the VDR, it would help explain how it blocks VDR function.
4.6 BAGp46 ca. repress traaSCripdOD ofp21"'"
The experiments presented in this thesis. show that BAGp46 can tr.lnsreprcss the cell
cycle inhibitor p21-n (Fig. 3.13 and 3.14). The exact mechanism of this repression remains
unknown. BAGp46 has previously been reported 10 inhibit RAR transactivalion (Liu et at.,
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fie 4.1 Possible medla.b• • fBAG-l actio8
Upper figure demonstrates transcriptional activation by the VDR. The VDR is
thought to bend the DNA o(the promoter contai.n.ing a VDRE enabling it to bind the
TFIIB protein of the basal transcriptional machinery. This results an increase in the rate
of transcription for such genes as p21-t1
The lower figure displays a proposed mechanism by which BAGpSO may inhibit
vitamin 0 action. BAGpSO disables the ability ofVDR to bind DNA and interact with
TFIIB. thus prcvetlting an increase in the rate oftranseription. BAGp46 may complement
the action ofBAGp50 by down.regulating p21'""" transcription through an unknown
mechanism.
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1998). In addition, the p21-" promoter region is known to contain an RARE and is
transaetivated through this motifby the RAR (Liu et al., 1996). Therefore. it is possible that
BAGp46 may inhibit the transactivation ofp21-" irtclim:tly via inhibition of the RAR.
Furthcrcxpcriments using various deletions ofthe p21..n promoter region cocransfceted with
BAGp46 could confirm this theory. Also. further work should be performed using Nonhem
blots (RNA from BAGp46 tnnsfected cells probed for endogenous p21 wofI expression) to
further demonstrate that this transcription repression may have physiological relevance.
Overall, these results also suggests thai diffeTent isofonns of BAG·) may work
collaboratively to achieve a common goal (Fig. 4.1). Different isoforms of BAG· I may be
able to promote proliferation through regulation aCthe various steroid hormone receptors.
BAG~I may have evolved to make multiple isoforms so that it could regulate multiple
honnone receptors simultaneously. It would be interesting 10 know if BAG· I transcription
is regulated by hormone receptors, since this would create a mechanism of receptor auto-
regulation.
4.7 BAG-l expressloD
BAG·I was found to be expressed in a wide variety of tissue types (Fig. 3.10). It is
difficult to draw conclusions as to the physiological function of BAG·! from this expression
pattern. BAG-I was found at high levels in several honnone responsive tissues, such as the
prostate. testis, thyroid and adrenal gland indicating that BAG-I may playa ro!I'! in honnone
signal transduction in these tissues. A good model for this would be in glands such as the
prostate, in which cell growth can be inhibited by 1.25·vitamin 03 (Zhuang and Burnstein
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1998) and enhanced by androgens (Scbuunnans et al., 1991). It is possible that BAGpSO
may simultaneously enhance AR function (Froesc:het aJ., 1997) and suppress VDR function.
In this manner, cells couJd regulate hormone pathways., ill~ in part, by controlling BAG·
1 levels.
Of the four immune system-rewed components (peripheral blood leukocytes,
thymus, lymph nodes and spleen) itudicd, BAG-l was observed at very low levels in
peripheral blood leukocytes and the thymus.. with lymph node tissue being the only one with
significant amounts of BAG-I mRNA present. All ofthese tissues are known to be targets
of glucocorticoid action with an end result of apoptosis in the white blood cells involved
(Cohen 1992, Horigomeetal.• 1997 and Wang et aJ., 1999). The thymus has recently been
found to express the GR at a level four times higher than splenic immune tissue. BAG-I
protein levels have been reponed to be controlled by glucocorticoids (Clevenger et al.•
1997). Our results and the results of past studies indicate the pertinence oflhis regulation
occurring in vivo.
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